Remedy Ledger

Remedies › Berberine › Cholesterol and blood fats · All remedies for cholesterol and blood fats

Berberine and cholesterol and blood fats: what the evidence says

Based on the evidence, berberine lowers LDL cholesterol and triglycerides by a small amount, though most trials were small, short, from China and judged at high risk of bias.

4/5 Moderate

At least one well-run randomized trial in people on this outcome, with a positive result. How we score

Every meta-analysis we read found lower LDL ('bad') cholesterol and triglycerides with berberine. The most careful one, limited to 18 placebo-controlled trials, found LDL 0.46 mmol/L (about 18 mg/dL) lower and triglycerides 0.34 mmol/L lower; the authors call these small reductions.

15 of those 18 trials (83%) were run in mainland China or Hong Kong, and earlier reviews judged most lipid trials low quality, with high risk of bias and very different results from trial to trial.

Not every analysis agrees. A 2024 review of 41 trials found LDL clearly lower with berberine combination products, but for berberine alone the LDL drop (-9.26 mg/dL) was not statistically certain. Against statins, berberine alone did not lower LDL more.

Recent large trials support a small effect: a 2026 trial of 337 people at 11 Chinese hospitals found LDL 7.72 mg/dL lower than placebo after six months, and a Hong Kong trial in 84 men found total cholesterol 0.39 mmol/L lower.

Many European products sold for cholesterol mix berberine with red yeast rice, which contains a natural statin, so their results cannot be credited to berberine. No trial has measured heart attacks or strokes.

We screened all 123 human-study records and read 43 abstracts in full: 23 of the 31 systematic reviews (the rest covered animal studies, stroke, liver disease or red yeast rice alone) and 20 of the 71 trials, choosing the largest and the placebo-controlled ones.

The evidence ladder higher rungs count for more
  1. Meta-analyses of trialspooled randomized trials9
  2. Human studiestrials and population studies8
  3. Case reportssingle people0
  4. Animal studiesmostly rodents514
  5. Lab studiescells, test tubes397

The studies in people, read one by one

ResultTypeWhat they didWhat they found
PositiveSystematic review / meta-analysis, 2023
1,788 people
Meta-analysis of 18 placebo-controlled randomized trials (University of Hong Kong, registered in PROSPERO)
Measured: LDL, triglycerides, HDL
LDL -0.46 mmol/L (95% CI -0.62 to -0.30), triglycerides -0.34 mmol/L; 15 of 18 trials from China or Hong Kong; stomach and bowel side effects 2-23% vs 2-15% on placebo. PubMed 36941490
PositiveSystematic review / meta-analysis, 2018
2,147 people
Meta-analysis of 16 randomized trials in high cholesterol
Measured: Total cholesterol, LDL, triglycerides
LDL -0.38 mmol/L (95% CI -0.53 to -0.22); trials judged mostly low quality with high risk of selection, performance and detection bias. PubMed 30466986
PositiveSystematic review / meta-analysis, 2013
874 people
Meta-analysis of 11 randomized trials
Measured: Blood lipids
LDL -0.65 mmol/L (95% CI -0.76 to -0.54); methodological quality of the trials generally low. PubMed 23512497
PositiveSystematic review / meta-analysis, 2020
3,042 people
Meta-analysis of 25 randomized trials (Chinese and English databases)
Measured: Blood lipids
Lower total cholesterol, triglycerides and LDL; high clinical heterogeneity and generally low methodological quality. PubMed 32237527
MixedSystematic review / meta-analysis, 2024
4,838 people
Meta-analysis of 41 randomized trials of berberine and berberine combination products (University of Connecticut)
Measured: LDL, triglycerides
Combination products: LDL -14.98 mg/dL; berberine alone: LDL -9.26 mg/dL (95% CI -20.31 to 1.78, not significant), triglycerides -17.40 mg/dL. PubMed 37183391
MixedSystematic review / meta-analysis, 2019
1,386 people
Meta-analysis of 11 randomized trials, berberine alone or with statins
Measured: LDL, triglycerides
Better than placebo; against simvastatin, no difference in LDL and only triglycerides lower; study quality called unsatisfactory. PubMed 31094214
MixedSystematic review / meta-analysis, 2023
4,606 people
Meta-analysis of 44 randomized trials in heart and blood-vessel disease
Measured: Blood lipids
Berberine alone was no different from routine treatment or statins for any lipid; berberine added to statins lowered cholesterol further. PubMed 36805484
PositiveSystematic review / meta-analysis, 2017Systematic review of 12 randomized trials
Measured: LDL, triglycerides
Most trials reported LDL reductions of roughly 20-50 mg/dL; common problems with blinding and reporting. PubMed 29228784
PositiveSystematic review / meta-analysis, 2016
3,924 people
Meta-analysis of 11 randomized trials of a combination product (berberine, policosanol, red yeast rice)
Measured: Blood lipids
LDL down 13.7% from baseline; red yeast rice in the product contains a natural statin, so the effect is not berberine's alone. PubMed 27131395
PositiveRandomized trial, 2026
337 people
Randomized, double-blind, placebo-controlled, 11 hospitals in China, obesity with fatty liver, 1 g a day for 6 months
Measured: LDL, belly fat, liver fat
LDL -7.72 mg/dL vs placebo (95% CI -13.13 to -1.93) and apolipoprotein B lower; no change in belly or liver fat. PubMed 41543854
PositiveRandomized trial, 2008
116 people
Randomized, placebo-controlled, type 2 diabetes with high cholesterol, 1 g a day for 3 months
Measured: Lipids
LDL 3.23 to 2.55 mmol/L and triglycerides 2.51 to 1.61 mmol/L, both significant against placebo. PubMed 18397984
PositiveRandomized trial, 2021
84 people
Randomized, double-blind, placebo-controlled, Chinese men with high cholesterol, 500 mg twice daily for 12 weeks (Hong Kong)
Measured: Total and LDL cholesterol
Total cholesterol -0.39 mmol/L (95% CI -0.70 to -0.08); LDL possibly lower; HDL also fell slightly. PubMed 34444711
PositiveRandomized trial, 2013
144 people
Randomized, double-blind, placebo-controlled with stop-and-restart design, low-risk Italian adults
Measured: Lipids
Cholesterol, triglycerides and LDL fell vs placebo, worsened when stopped, and improved again on restarting. PubMed 23441841
PositiveRandomized trial, 2016
97 people
Randomized, placebo-controlled, mild high cholesterol, 300 mg three times daily, with washout (China)
Measured: Lipids
Triglycerides, total cholesterol and LDL lower than placebo after the second treatment period (P < 0.05). PubMed 27491226
PositiveRandomized trial, 2008
63 people
Berberine, simvastatin or both in people with high cholesterol
Measured: LDL
The combination lowered LDL by 31.8%, more than either alone. PubMed 18640378
PositiveClinical trial, 2004
32 people
Uncontrolled 3-month trial in high cholesterol, with hamster and cell work (Nature Medicine)
Measured: Cholesterol, LDL
Cholesterol -29%, triglycerides -35%, LDL -25%; no comparison group. PubMed 15531889
PositiveRandomized trial, 2020
50 people
Randomized, placebo-controlled dose study of HTD1801 (berberine ursodeoxycholate, a drug form) for 28 days
Measured: LDL
At 2,000 mg a day, LDL -10.4% and total cholesterol -8.2%; triglycerides and HDL unchanged. PubMed 33183320

Where the sources agree, and where they don’t

3 of 6 kinds of source point toward a benefit, 1 toward no effect or harm, 2 are mixed. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.

Kind of sourcePoints toDetail
Meta-analyses of trialsPositiveLDL about 0.4-0.6 mmol/L lower; high risk of bias
Berberine alone, 2024 reviewMixedLDL drop not statistically certain
Against statinsNo effectno better than statins
Recent large trial (2026)PositiveLDL 7.7 mg/dL lower, 337 people
PatentsPositivehyperlipidemia patents in 7 offices (a claim)
Public reportsMixed1 helped, 1 no effect, 1 worse

What people report

We read public first-person posts and counted every outcome, good or bad. 3 reports about this condition, read on 2026-10-28; 0 mention side effects.

  • 1Helped
  • 1No effect
  • 1Got worse
  • 0Mixed
  • 0Too early

Why these counts prove nothing on their own: people who post are not a random sample, most take other treatments at the same time, and nobody checks the diagnosis. We show them because they tell researchers what to test next.

Read all 3 reports
  • Helped Cannot tolerate metformin, so takes 500 mg twice daily instead; says cholesterol is better and has had no side effects. Diabetes.co.uk forum, 2023-10-19 (No numbers; glucose effect not described.)
  • Worse Over a 3.5-month trial, triglycerides rose 15%, LDL rose 2 points and HDL fell 10%. QVC Community, 2024-09 (Diet changed at the same time; small LDL change may be noise; thread posts dated September 2024.)
  • No effect Took berberine with red yeast rice and other supplements for a long stretch on a cardiologist's advice with no improvement. QVC Community, 2024-09 (Familial high cholesterol; now on a prescription injection that works.)

Every other paper we found

PubMed returned 1,171 papers for this search on 2026-10-28. We read the human studies above ourselves. The rest are sorted by type automatically from PubMed's labels, which are sometimes wrong. We removed 13 papers that only share a word with this search.

Animal studies 514
  1. Optimization of Vinegar Processing for Yuanhu Zhitong Formula Enhances Antigastric Ulcer Efficacy: An Integrated Pharmacokinetic-Pharmacodynamic and Network Pharmacology Study. Biomed Chromatogr, 2026
  2. Hepatorenal protective effect of berberine-loaded Ag-ZnO nanoparticles in mitigating carbon tetrachloride (direct) and alloxan-induced oxidative stress (indirect) in albino rat models. RSC Adv, 2026
  3. Antibiotic-sparing efficacy of a berberine-colistin combination in piglet diarrhea: Clinical outcomes and host-directed mechanisms. Res Vet Sci, 2026
  4. Effect of Berberine on Improving Reproduction Disorder in Female Mice with Type 2 Diabetes Mellitus. Chin J Integr Med, 2026
  5. Berberine's Role in Modulating Gut Microbiota and Endocannabinoid System in Colitis-Associated Colorectal Cancer. Mol Nutr Food Res, 2026
  6. Berberine Stabilizes the Arrhythmogenic Substrate in Obese Rats by Klotho-Mediated Attenuation of Oxidative Stress and Inflammation. Int J Mol Sci, 2026
  7. The Protective Effects of Small-Molecule Compound 0242 Against LPS-Induced Neuroinflammation and in P301S Tau Transgenic Mice. Neurochem Res, 2026
  8. Huanglian wendan decoction attenuates hepatic inflammation and lipogenesis via inhibition of the NF-κB/HDAC1/SREBP-1c axis. J Ethnopharmacol, 2026
  9. Probing the interactions between bovine hemoglobin and three berberine saturated fatty acid salts by multi-spectral techniques, conductimetry and molecular docking. Biophys Chem, 2026
  10. Oral Administration of Berberine-Based Carbon Dots Target Ferric Iron to Alleviate Atherosclerosis. ACS Appl Mater Interfaces, 2026
  11. Protective effects of Fraxinus xanthoxyloides bark in alloxan-induced diabetic rats: A phytochemical and pharmacological approach. PLoS One, 2026
  12. The lipid-modulating effect of berberine in hyperlipidemic ApoE-/- mice. Front Pharmacol, 2026
  13. Dual inhibition of caspase-11 pyroptosis and NLRP3 inflammasome by Huanglian Jiedu Decoction: A polypharmacological strategy for sepsis management. Phytomedicine, 2026
  14. Berberine alleviates LPS-induced inflammatory response by targeted activation of NR1D1 in bovine endometrial epithelial cells. Int Immunopharmacol, 2026
  15. Targeting the PI3K/Akt/mTOR and Nrf2 signaling axis with berberine: a novel strategy for attenuating diabetic cardiomyopathy. Naunyn Schmiedebergs Arch Pharmacol, 2026
  16. A multifunctional lipid-lowering nanotherapeutic alleviates lipid deposition associated microglial dysfunction. Nanomedicine (Lond), 2026
  17. Integrated analysis of network pharmacology and multi-omics reveals the mechanisms of Zuogui Jiangtang Qinggan formula ameliorates MASLD via fatty acid metabolic reprogramming. Phytomedicine, 2026
  18. The anti-ulcerative potential of Berberine on the rat model of inflammatory bowel disease. J Mol Histol, 2026
  19. Berberine chloride-loaded polymeric lipid hybrid nanoparticles ameliorate cognitive impairment by reducing phosphorylation of tau at threonine 231. Nanomedicine, 2026
  20. Epi-Berberine Alleviates Ulcerative Colitis, Protects the Intestinal Mucosal Barrier, and Inhibits Colonic Inflammation via Glutaminyl-Peptide Cyclotransferase in a Mouse Model of DSS-Induced Colitis. Phytother Res, 2026
  21. Lacticaseibacillus paracasei 36 attenuates D-GalN/LPS-induced acute liver injury in mice via suppressing the TLR4/NF-κB/MAPK pathway and NLRP3 inflammasome activation through modulating the intestinal microbiota. J Adv Res, 2026
  22. Berberine alleviates pre-eclampsia by modulating M1/M2 macrophage polarization and T helper (Th1/Th2) cells cytokine balance. Br J Pharmacol, 2026
  23. Berberine Alleviates Lipopolysaccharide-Induced Impairments in Neuroplasticity and Spatial Memory by Modulating Microglial Polarization via MAPK Signaling Inhibition. Neural Plast, 2026
  24. Nanoparticle-Based Oral Delivery of Berberine Attenuates High-Fat Diet-Induced Hepatic Steatosis in Mice: Insights from Integrated Hepatic Metabolomic and Transcriptomic Analyses. J Agric Food Chem, 2026
  25. Berberine Alleviates Lipopolysaccharide-Induced Acute Lung Injury by Modulating the AMPK-HMGB1-NF-κB Signaling Axis. Front Biosci (Landmark Ed), 2026
  26. Nanostructured lipid nanoparticles delivering berberine with Se coating: a new nanotherapeutic approach against cryptosporidiosis. Pharm Dev Technol, 2026
  27. Neuroprotective effect of berberine-loaded niosomes against brain injury in dyslipidemic rats: The interplay between oxidative stress, mitochondrial dysfunction and apoptotic signals. Biochim Biophys Acta Mol Cell Biol Lipids, 2026
  28. Astragalus licorice prescription and its active components alleviate chemotherapy-induced intestinal mucositis by apoptosis and fatty acid β-oxidation: Integrative multi-omics approaches. Phytomedicine, 2026
  29. Berberine suppresses colon inflammation via integrated modulation of host metabolism, microbial ecology, and innate immune signaling. Theranostics, 2026
  30. Exploring the gut-kidney axis: Berberine's role in alleviating chronic kidney disease through microbiota and short-chain fatty acids. J Ethnopharmacol, 2026
  31. Berberine rescues PANoptosis-Driven hemophagocytic lymphohistiocytosis via cardiolipin-mediated mitochondrial stabilization. Eur J Pharmacol, 2026
  32. Evaluation of the obesogenic role of betel nut extract in mice and its remediation by berberine and orlistat. Toxicon, 2026
  33. Design and synthesis of protoberberine analogues to alleviate LPS-induced acute lung injury by targeting HCK and blocking the HCK-NLRP3 axis. Eur J Med Chem, 2026
  34. Coptidis Rhizome alleviates dexamethasone- and fructose-induced metabolic disorder in rats as an inducer of HO-1 agonist via erythrocyte metabolism. J Ethnopharmacol, 2026
  35. A combination of tetramethylpyrazine and berberine prevents coronary microembolization in rats by regulating miR-34a-5p in platelet-derived exosomes. J Ethnopharmacol, 2026
  36. Jiao-tai-wan and its bioactive constituent jatrorrhizine exert antidepressant effects via the STING pathway. J Ethnopharmacol, 2026
  37. Berberine Alleviates Chronic Restraint Stress-Induced Depression-Like Behavior by Modulating Gut Microbiota and SCFA Production in Mice. Biotechnol Appl Biochem, 2026
  38. Coptisine mitigates acute lung injury by alleviating ferroptosis through the PI3K/AKT/Nrf2 pathway. J Ethnopharmacol, 2026
  39. Neuroprotective Effects of Berberine Chloride Against the Aluminium Chloride-Induced Alzheimer's Disease in Zebra Fish Larvae. Mol Biotechnol, 2026
  40. Protective effects of berberine-loaded chitosan/solid lipid nanoparticles in streptozotocin-induced gestational diabetes mellitus rats. Exp Biol Med (Maywood), 2025
  41. Protective Effects of Berberine-Loaded Black Seed (Nigella sativa L.) Oil Nanoemulsion in the Atherosclerotic Mouse Model. Iran J Pharm Res, 2025
  42. Therapeutic potential of zinc oxide/berberine nanoparticles in mitigating acute respiratory distress syndrome: in vivo and in silico approaches. BMC Pharmacol Toxicol, 2025
  43. [Berberine inhibits macrophage foam cell formation through activation of ACE2-Ang(1-7)-Mas signaling pathway]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2025
  44. Overcoming Bioavailability Barriers: Optimized Hybrid Nanocarrier System to Amplify Berberine Absorption via Peyer's Patches. AAPS PharmSciTech, 2025
  45. Berberine Alleviates Intestinal Inflammation by Disrupting Pathological Macrophage-Epithelial Crosstalk in Macrophage-Organoid Co-Culture Model. Int J Mol Sci, 2025
  46. Jiao-tai-wan and its component coptisine attenuate PCOS by regulating mitochondrial cholesterol import through suppression of SIRT1 ubiquitination. Phytomedicine, 2025
  47. Metabolomics reveals the hindgut metabolic changes and physiological impacts in weaned piglets subjected to ETEC infection and berberine intervention. Sci Rep, 2025
  48. Coptisine alleviates intestinal barrier dysfunction and inflammation in TNBS-induced colitis rats and LPS-stimulated human intestinal Caco-2 cells. Int Immunopharmacol, 2025
  49. Integrated pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids in HFHCD-induced mice: Implications for pharmacokinetic variability in MASH treatment. Biomed Pharmacother, 2025
  50. Berberine ameliorates atherosclerosis by inhibiting the phenotypic transition of vascular smooth muscle cells via suppression of the JAK2/STAT3 signaling pathway. Eur J Pharmacol, 2025
  51. Diweng Zhixie Power Ameliorates Dampness-Heat Diarrhea by Restoring Intestinal Microbiota Dysbiosis and Short-Chain Fatty Acids. Biomed Chromatogr, 2025
  52. Mechanism of Huanglian Wendan Decoction in ameliorating non-alcoholic fatty liver disease via modulating gut microbiota-mediated metabolic reprogramming and activating the LKB1/AMPK pathway. PLoS One, 2025
  53. Antiarthritic activities of berberine in a rat model of gouty arthritis. Sci Rep, 2025
  54. Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment. Phytomedicine, 2025
  55. Effect of berberine on LPS-induced intestinal epithelial injury and m6A methylation in broilers. Poult Sci, 2025
  56. Ulcerative Colitis Aggravates Periodontitis via Inducing Myelopoiesis. Inflamm Bowel Dis, 2025
  57. Coptisine Improves Liver Inflammation in Sepsis by Regulating STAT1/IRF1/GPX4 Signaling-Mediated Kupffer Cells Ferroptosis. Phytother Res, 2025
  58. Berberine nanoemulsion attenuates bisphenol A-induced metabolic impairment through NF-κB signaling in the liver of rat. Toxicol Rep, 2025
  59. Exploring the Multi-Faceted Effects of Berberine in Ameliorating Diastolic Dysfunction in Rats with Heart Failure with Preserved Ejection Fraction. Int J Mol Sci, 2025
  60. Combination of Berberine and Evodiamine Alleviates Obesity by Promoting Browning in 3T3-L1 Cells and High-Fat Diet-Induced Mice. Int J Mol Sci, 2025
  61. Regulatory effect of atorvastatin combined with berberine on PI3K/AKT/FoxO1 signaling pathway in rats with hyperlipidaemia. Xenobiotica, 2025
  62. Exploring the bioactive components and mechanism of Biling Weitong Granules in chronic gastric ulcer repair through network analysis and experimental verification. Naunyn Schmiedebergs Arch Pharmacol, 2025
  63. Nutraceutical supplement slim reshaped colon histomorphology and reduces Mucispirillum schaedleri in obese mice. Front Microbiol, 2025
  64. Chinese herbal medicine improves antioxidant capacity of chicken liver at high stocking density involved gut-liver microbiota axis based on multi-omics technologies. Poult Sci, 2025
  65. Berberine Improves Ox-LDL-Induced Macrophage Efferocytosis Dysfunction and Alleviates Inflammation via the PPARγ/LXRα Pathway. Tohoku J Exp Med, 2025
  66. Study on the mechanism of action of berberine combined with Jianpi Yishen Huazhuo formulation in treating obese polycystic ovary syndrome by activating PI3K/AKT signaling pathway. Gynecol Endocrinol, 2025
  67. Role of berberine in metabolic and bone changes in ovariectomized rats. Arch Physiol Biochem, 2025
  68. Epiberberine Improves Hyperglycemia and Ameliorates Insulin Sensitivity in Type 2 Diabetic Mice. Nephrology (Carlton), 2025
  69. Coptisine improves LPS-induced anxiety-like behaviors by regulating the Warburg effect in microglia via PKM2. Biomed Pharmacother, 2025
  70. Berberine Improves Glucose and Lipid Metabolism in Obese Mice Through the Reduction of IRE1/GSK-3β Axis-Mediated Inflammation. Endocr Metab Immune Disord Drug Targets, 2025
  71. Unveiling nature's antidiabetic potential in Berberis orthobotrys seeds for alloxan-induced diabetic rats. Sci Rep, 2025
  72. Integrated HPLC, pharmacodynamics, and immunoprofiling to explore active components and mechanism of Zhi Bai Heye Fang on glycolipid metabolic disorders in mice. J Chromatogr B Analyt Technol Biomed Life Sci, 2025
  73. Integrating lipid metabolomics, serum medicinal chemistry, network pharmacology and experimental validation to explore the mechanism of Sanmiao wan in the treatment of rheumatoid arthritis. J Ethnopharmacol, 2025
  74. Potentiation and in vivo evaluation of anti-obesity activity of berberine through encapsulation in guar-acacia gum nanocomplexes. Naunyn Schmiedebergs Arch Pharmacol, 2025
  75. Thermosensitive Injectable Dual Drug-Loaded Chitosan-Based Hydrogels for Treating Bacterial Endometritis. ACS Biomater Sci Eng, 2024
  76. Nanocarrier-Assisted Delivery of Berberine Promotes Diabetic Alveolar Bone Regeneration by Scavenging ROS and Improving Mitochondrial Dysfunction. Int J Nanomedicine, 2024
  77. Berberine inhibits LPS-induced epithelial-mesenchymal transformation by activating the Nrf2 signalling pathway in bovine endometrial epithelial cells. Int Immunopharmacol, 2024
  78. Berberine and palmatine, acting as allosteric potential ligands of α7 nAChR, synergistically regulate inflammation and phagocytosis of microglial cells. FASEB J, 2024
  79. [Mechanism of berberine in improving adipocytic IR by mediating BMAL1:CLOCK complex and regulating glucose and lipid metabolism]. Zhongguo Zhong Yao Za Zhi, 2024
  80. Jiao-tai-wan and its effective component-coptisine alleviate cognitive impairment in db/db mice through the JAK2/STAT3 signaling pathway. Phytomedicine, 2024
  81. Berberine alleviates ulcerative colitis by inhibiting inflammation through targeting IRGM1. Phytomedicine, 2024
  82. The effects of berberine and curcumin on cardiac, lipid profile and fibrosis markers in cyclophosphamide-induced cardiac damage: The role of the TRPM2 channel. J Biochem Mol Toxicol, 2024
  83. Protective Effects of Berberine on Nonalcoholic Fatty Liver Disease in db/db Mice via AMPK/SIRT1 Pathway Activation. Curr Med Sci, 2024
  84. Enhancing hepatoprotective action: oxyberberine amorphous solid dispersion system targeting TLR4. Sci Rep, 2024
  85. Interactions of three berberine mid-chain fatty acid salts with bovine serum albumin (BSA): Spectroscopic analysis and molecular docking. Int J Biol Macromol, 2024
  86. Multifunctional composite soluble microneedle patch based on "one stone, three birds" strategy for promoting the healing of infectious wounds. Colloids Surf B Biointerfaces, 2024
  87. Berberine alleviates cholesterol and bile acid metabolism disorders induced by high cholesterol diet in mice. Biochem Biophys Res Commun, 2024
  88. Restoring colistin sensitivity in colistin-resistant Salmonella and Escherichia coli: combinatorial use of berberine and EDTA with colistin. mSphere, 2024
  89. Berberine attenuates obesity-induced insulin resistance by inhibiting miR-27a secretion. Diabet Med, 2024
  90. Mechanism of the components compatibility of Scutellariae Radix and Coptidis Rhizoma on mice with hyperlipidemia by regulating the Cyp4a family. J Ethnopharmacol, 2024
  91. Intelligent berberine-loaded erythrocytes attenuated inflammatory cytokine productions in macrophages. Sci Rep, 2024
  92. Atorvastatin-induced intracerebral hemorrhage is inhibited by berberine in zebrafish. J Appl Toxicol, 2024
  93. Evaluation of Antioxidant Activity and Treatment of Eczema by Berberine Hydrochloride-Loaded Liposomes-in-Gel. Molecules, 2024
  94. Coptisine protects against transient focal cerebral ischaemic injury by regulation of arachidonic acid metabolism. J Pharm Pharmacol, 2024
  95. Berberine alleviates concanavalin A-induced autoimmune hepatitis in mice by modulating the gut microbiota. Hepatol Commun, 2024
  96. Beneficial Effects of Natural Alkaloids from Berberis glaucocarpa as Antidiabetic Agents: An In Vitro, In Silico, and In Vivo Approach. ACS Omega, 2024
  97. Berberine attenuates inflammation and oxidative stress and modulates lymphocyte E-NTPDase in acute hyperlipidemia. Drug Dev Res, 2024
  98. A Dual Therapeutic Approach to Diabetes Mellitus via Bioactive Phytochemicals Found in a Poly Herbal Extract by Restoration of Favorable Gut Flora and Related Short-Chain Fatty Acids. Appl Biochem Biotechnol, 2024
  99. Tetrahydroberberine alleviates high-fat diet-induced hyperlipidemia in mice via augmenting lipoprotein assembly-induced clearance of low-density lipoprotein and intermediate-density lipoprotein. Eur J Pharmacol, 2024
  100. Film-forming polymer solutions containing cholesterol myristate and berberine mediate pressure ulcer repair via the Wnt/β-catenin pathway. Wound Repair Regen, 2024
  101. Effects of Berberine on glucolipid metabolism among dehydroepiandrosterone-induced rats of polycystic ovary syndrome with insulin-resistance. Heliyon, 2024
  102. Berberine attenuates cognitive dysfunction and hippocampal apoptosis in rats with prediabetes. Chem Biol Drug Des, 2024
  103. Berberine alleviates inflammation and suppresses PLA2-COX-2-PGE2-EP2 pathway through targeting gut microbiota in DSS-induced ulcerative colitis. Biochem Biophys Res Commun, 2024
  104. A neutral polysaccharide from Persicaria hydropiper (L.) Spach ameliorates lipopolysaccharide-induced intestinal barrier injury via regulating the gut microbiota and modulating AKT/PI3K/mTOR and MAPK signaling pathways. J Ethnopharmacol, 2024
  105. Sanhuang Xiexin Decoction Ameliorates TNBC By Modulating JAK2-STAT3 and Lipid Metabolism. Chin J Integr Med, 2024
  106. Huangqin-Huanglian Decoction Protects Liver against Non-alcoholic Fatty Liver Disease in High Fat-diet Mice. Endocr Metab Immune Disord Drug Targets, 2024
  107. Berberine loaded thermosensitive lipid nanoparticles: in vitro characterization, in silico study, and in vivo anti-arthritic effect. J Liposome Res, 2024
  108. Investigation of Antioxidant and Anti-inflammatory Properties of Berberine Nanomicelles: In vitro and In vivo Studies. Curr Drug Deliv, 2024
  109. Yunvjian decoction attenuates lipopolysaccharide-induced periodontitis by suppressing NFκB/NLRP3/IL-1β pathway. J Ethnopharmacol, 2024
  110. Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism. J Ethnopharmacol, 2024
  111. Assessing the Efficacy of Berberine Hydrochloride-loaded Transethosomal Gel System in Treating Dermatophytosis Caused by Trichophyton rubrum in ex-vivo, in-vitro and in-vivo Models. Curr Drug Res Rev, 2024
  112. Therapeutic Effect and Mechanism Prediction of Fuzi-Gancao Herb Couple on Non-alcoholic Fatty Liver Disease (NAFLD) based on Network Pharmacology and Molecular Docking. Comb Chem High Throughput Screen, 2024
  113. Berberine Mediates the Production of Butyrate to Ameliorate Cerebral Ischemia via the Gut Microbiota in Mice. Nutrients, 2023
  114. Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats. Xenobiotica, 2023
  115. Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis. Biochem Pharmacol, 2023
  116. Protective effects of berberine in chronic copper-induced liver and gill injury in freshwater grouper (Acrossocheilus fasciatus). Ecotoxicol Environ Saf, 2023
  117. RETRACTED: Bioassays guided isolation of berberine from Berberis lycium and its neuroprotective role in aluminium chloride induced rat model of Alzheimer's disease combined with insilico molecular docking. PLoS One, 2023
  118. Berberine ameliorates renal interstitial inflammation and fibrosis in mice with unilateral ureteral obstruction. Basic Clin Pharmacol Toxicol, 2023
  119. Comparing the Influences of Metformin and Berberine on the Intestinal Microbiota of Rats With Nonalcoholic Steatohepatitis. In Vivo, 2023
  120. Ameliorative effects of the Coptis inflorescence extract against lung injury in diabetic mice by regulating AMPK/NEU1 signaling. Phytomedicine, 2023
  121. Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPARδ. Int J Mol Sci, 2023
  122. Berberine enhances autophagic flux by activating the Nrf2 signaling pathway in bovine endometrial epithelial cells to resist LPS-induced apoptosis. Anim Sci J, 2023
  123. Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice. Gastroenterol Rep (Oxf), 2023
  124. Intestines-erythrocytes-mediated bio-disposition deciphers the hypolipidemic effect of berberine from Rhizoma Coptidis: A neglected insight. J Ethnopharmacol, 2023
  125. DSPE-PEG polymer enhanced berberine absorption specifically in the small intestine of rats through paracellular passway. J Pharm Pharmacol, 2023
  126. Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling. Front Immunol, 2023
  127. Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine. Int J Biol Sci, 2023
  128. Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma. Phytomedicine, 2023
  129. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. Biomed Pharmacother, 2023
  130. Antidiabetic activity of Berberis brandisiana is possibly mediated through modulation of insulin signaling pathway, inflammatory cytokines and adipocytokines in high fat diet and streptozotocin-administered rats. Front Pharmacol, 2023
  131. Acetylation of p65Lys310 by p300 in macrophages mediates anti-inflammatory property of berberine. Redox Biol, 2023
  132. Autophagic degradation of LOX-1 is involved in the maintenance of vascular integrity injured by oxLDL and protected by Berberine. Int J Biol Sci, 2023
  133. Banxia Xiexin decoction alleviates AS co-depression disease by regulating the gut microbiome-lipid metabolic axis. J Ethnopharmacol, 2023
  134. Assessment of anti-arthritic activity of lipid matrix encased berberine in rheumatic animal model. J Microencapsul, 2023
  135. LCN2 contributes to the improvement of nonalcoholic steatohepatitis by 8-Cetylberberine. Life Sci, 2023
  136. Caffeine can alleviate non-alcoholic fatty liver disease by augmenting LDLR expression via targeting EGFR. Food Funct, 2023
  137. New insights into the role of berberine against 3-nitropropionic acid-induced striatal neurotoxicity: Possible role of BDNF-TrkB-PI3K/Akt and NF-κB signaling. Food Chem Toxicol, 2023
  138. Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents. Molecules, 2023
  139. Berberine Ameliorates Abnormal Lipid Metabolism via the Adenosine Monophosphate-Activated Protein Kinase/Sirtuin 1 Pathway in Alcohol-Related Liver Disease. Lab Invest, 2023
  140. A High Dose of Dietary Berberine Improves Gut Wall Morphology, Despite an Expansion of Enterobacteriaceae and a Reduction in Beneficial Microbiota in Broiler Chickens. mSystems, 2023
  141. Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitis. Biochim Biophys Acta Mol Basis Dis, 2023
  142. Antinociceptive effect and identification of berberine alkaloid in Berberis ruscifolia extracts. J Ethnopharmacol, 2023
  143. Effects of dietary berberine on growth performance, lipid metabolism, antioxidant capacity and lipometabolism-related genes expression of AMPK signaling pathway in juvenile black carp (Mylopharyngodon piceus) fed high-fat diets. Fish Physiol Biochem, 2023
  144. The Berberis vulgaris L. extract berberine exerts its anti-oxidant effects to ameliorate cholesterol overloading-induced cell apoptosis in the primary mice hepatocytes: an in vitro study. In Vitro Cell Dev Biol Anim, 2022
  145. Macrophage-Targeted Berberine-Loaded β-Glucan Nanoparticles Enhance the Treatment of Ulcerative Colitis. Int J Nanomedicine, 2022
  146. Inhibition of inflammasome activation via sphingolipid pathway in acute lung injury by Huanglian Jiedu decoction: An integrative pharmacology approach. Phytomedicine, 2022
  147. The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression. Biomed Pharmacother, 2022
  148. [Effects of berberine on LPS /NF-κB and MAPK signaling pathways in PCOS model rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2022
  149. Berberine Ameliorates Lipopolysaccharide-Induced Cognitive Impairment Through SIRT1/NRF2/NF-κB Signaling Pathway in C57BL/6J Mice. Rejuvenation Res, 2022
  150. Berberine attenuates diabetic atherosclerosis via enhancing the interplay between KLF16 and PPARα in ApoE-/- mice. Biochem Biophys Res Commun, 2022
  151. Berberine Ameliorate Haloperidol and 3-Nitropropionic Acid-Induced Neurotoxicity in Rats. Neurochem Res, 2022
  152. Retraction Note to: Modulatory Effects of Berberine Chloride on Lipid Profile, Oxidant Status and Insulin Signaling Molecules in Streptozotocin Induced Diabetic Rats. Indian J Clin Biochem, 2022
  153. A New Berberine Preparation Protects Pancreatic Islet Cells from Apoptosis Mediated by Inhibition of Phospholipase A2/p38 MAPK Pathway. Bull Exp Biol Med, 2022
  154. Jatrorrhizine from Rhizoma Coptidis exerts an anti-obesity effect in db/db mice. J Ethnopharmacol, 2022
  155. Protective effect of oxyberberine against acute lung injury in mice via inhibiting RhoA/ROCK signaling pathway. Biomed Pharmacother, 2022
  156. Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats. Food Funct, 2022
  157. Modulation of Gut Microbiota and Metabolites by Berberine in Treating Mice With Disturbances in Glucose and Lipid Metabolism. Front Pharmacol, 2022
  158. Solid Lipid Nanoformulation of Berberine Attenuates Doxorubicin Triggered in vitro Inflammation in H9c2 Rat Cardiomyocytes. Comb Chem High Throughput Screen, 2022
  159. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora. Phytomedicine, 2022
  160. Berberine protects against palmitate induced beta cell injury via promoting mitophagy. Genes Genomics, 2022
  161. Vagus nerve stimulated by microbiota-derived hydrogen sulfide mediates the regulation of berberine on microglia in transient middle cerebral artery occlusion rats. Phytother Res, 2022
  162. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway In Vivo and In Vitro. Front Pharmacol, 2022
  163. Berberine alleviates NLRP3 inflammasome induced endothelial junction dysfunction through Ca2+ signalling in inflammatory vascular injury. Phytomedicine, 2022
  164. Chitosan-Coated Solid Lipid Nano-Encapsulation Improves the Therapeutic Antiairway Inflammation Effect of Berberine against COPD in Cigarette Smoke-Exposed Rats. Can Respir J, 2022
  165. Hydrochloride Berberine ameliorates alcohol-induced liver injury by regulating inflammation and lipid metabolism. Biochem Biophys Res Commun, 2022
  166. Berberine reduces hepatic ceramide levels to improve insulin resistance in HFD-fed mice by inhibiting HIF-2α. Biomed Pharmacother, 2022
  167. Berberine Modulates Macrophage Activation by Inducing Glycolysis. J Immunol, 2022
  168. Gegen Qinlian pills alleviate carrageenan-induced thrombosis in mice model by regulating the HMGB1/NF-κB/NLRP3 signaling. Phytomedicine, 2022
  169. Sinomenine inhibits macrophage M1 polarization by downregulating α7nAChR via a feedback pathway of α7nAChR/ERK/Egr-1. Phytomedicine, 2022
  170. [Berberine alleviates programmed necrosis of metabolic-associated fatty liver disease via activating Nrf2 pathway in mice]. Zhonghua Gan Zang Bing Za Zhi, 2022
  171. Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. Front Pharmacol, 2022
  172. Antipyretic Mechanism Exploration of HuanglianShangqing Pill Based on Metabolomics and Network Pharmacology. Comb Chem High Throughput Screen, 2022
  173. Discovery and structural optimization of 9-O-phenylsulfonyl-berberines as new lipid-lowering agents. Bioorg Chem, 2022
  174. Natural history-guided omics reveals plant defensive chemistry against leafhopper pests. Science, 2022
  175. Berberine-loaded liposomes for oral delivery: Preparation, physicochemical characterization and in-vivo evaluation in an endogenous hyperlipidemic animal model. Int J Pharm, 2022
  176. Berberine alleviates LPS-induced apoptosis, oxidation, and skewed lineages during mouse preimplantation development†. Biol Reprod, 2022
  177. Berberine ameliorates erectile dysfunction in rats with streptozotocin-induced diabetes mellitus through the attenuation of apoptosis by inhibiting the SPHK1/S1P/S1PR2 and MAPK pathways. Andrology, 2022
  178. Berberine-loaded nanostructured lipid carriers mitigate warm hepatic ischemia/reperfusion-induced lesion through modulation of HMGB1/TLR4/NF-κB signaling and autophagy. Biomed Pharmacother, 2022
  179. Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway. Ann Transl Med, 2021
  180. Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation. Pharm Res, 2021
  181. Orally Deliverable Dual-Targeted Pellets for the Synergistic Treatment of Ulcerative Colitis. Drug Des Devel Ther, 2021
  182. Berberine inhibited carotid atherosclerosis through PI3K/AKTmTOR signaling pathway. Bioengineered, 2021
  183. Berberine loaded nanostructured lipid carrier for Alzheimer's disease: Design, statistical optimization and enhanced in vivo performance. Life Sci, 2021
  184. Berberine combined with stachyose improves glycometabolism and gut microbiota through regulating colonic microRNA and gene expression in diabetic rats. Life Sci, 2021
  185. Chronoeffects of the Herbal Medicines Puerariae radix and Coptidis rhizoma in Mice: A Potential Role of REV-ERBα. Front Pharmacol, 2021
  186. Berberine elevates cardiolipin in heart of offspring from mouse dams with high fat diet-induced gestational diabetes mellitus. Sci Rep, 2021
  187. Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. Phytomedicine, 2021
  188. Lipid-Coated MCM-41 Mesoporous Silica Nanoparticles Loaded with Berberine Improved Inhibition of Acetylcholine Esterase and Amyloid Formation. ACS Biomater Sci Eng, 2021
  189. Berberine administrated with different routes attenuates inhaled LPS-induced acute respiratory distress syndrome through TLR4/NF-κB and JAK2/STAT3 inhibition. Eur J Pharmacol, 2021
  190. Study on the compatibility effect and active constituents of Atractylodis Rhizoma in Ermiao Wan against Acute Gouty Arthritis. J Ethnopharmacol, 2021
  191. The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease. Iran J Basic Med Sci, 2021
  192. The Combination of Berberine, Tocotrienols and Coffee Extracts Improves Metabolic Profile and Liver Steatosis by the Modulation of Gut Microbiota and Hepatic miR-122 and miR-34a Expression in Mice. Nutrients, 2021
  193. Berberine ameliorates the LPS-induced imbalance of osteogenic and adipogenic differentiation in rat bone marrow-derived mesenchymal stem cells. Mol Med Rep, 2021
  194. [Berberine dose-dependently inhibits the expression of procoagulant and fibrinolytic inhibitory factors in lipopolysaccharide-induced rat type II alveolar epithelial cells]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 2021
  195. Berberine attenuates septic cardiomyopathy by inhibiting TLR4/NF-κB signalling in rats. Pharm Biol, 2021
  196. Dietary berberine can ameliorate glucose metabolism disorder of Megalobrama amblycephala exposed to a high-carbohydrate diet. Fish Physiol Biochem, 2021
  197. Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways. Cells, 2021
  198. An integrated network pharmacology and transcriptomic method to explore the mechanism of the total Rhizoma Coptidis alkaloids in improving diabetic nephropathy. J Ethnopharmacol, 2021
  199. Berberine alters gut microbial function through modulation of bile acids. BMC Microbiol, 2021
  200. Berberine alleviates palmitic acid‑induced podocyte apoptosis by reducing reactive oxygen species‑mediated endoplasmic reticulum stress. Mol Med Rep, 2021
  201. Berberine improves intralipid-induced insulin resistance in murine. Acta Pharmacol Sin, 2021
  202. Dietary berberine regulates lipid metabolism in muscle and liver of black sea bream (Acanthopagrus schlegelii) fed normal or high-lipid diets. Br J Nutr, 2021
  203. Berberine Nanoencapsulation Attenuates Hallmarks of Scoplomine Induced Alzheimer's-Like Disease in Rats. Curr Rev Clin Exp Pharmacol, 2021
  204. Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway. Turk J Gastroenterol, 2020
  205. Berberine for Appetite Suppressant and Prevention of Obesity. Biomed Res Int, 2020
  206. Anti‑inflammatory mechanism of berberine on lipopolysaccharide‑induced IEC‑18 models based on comparative transcriptomics. Mol Med Rep, 2020
  207. Anticolitic Effect of Berberine in Rat Experimental Model: Impact of PGE2/p38 MAPK Pathways. Mediators Inflamm, 2020
  208. [Berberine protects myocardial injury and cardiac dysfunction in a septic rat model]. Zhonghua Yi Xue Za Zhi, 2020
  209. Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori. J Control Release, 2020
  210. Berberine-Loaded Liposomes for the Treatment of Leishmania infantum-Infected BALB/c Mice. Pharmaceutics, 2020
  211. Berberine functions as a negative regulator in lipopolysaccharide -induced sepsis by suppressing NF-κB and IL-6 mediated STAT3 activation. Pathog Dis, 2020
  212. Berberine ameliorates rats model of combined Alzheimer's disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress. 3 Biotech, 2020
  213. Regulation of MFN2 by berberine alleviates obesity exacerbated colitis. Biochem Biophys Res Commun, 2020
  214. Anti-arthritis effect of berberine associated with regulating energy metabolism of macrophages through AMPK/ HIF-1α pathway. Int Immunopharmacol, 2020
  215. In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects. Int Immunopharmacol, 2020
  216. Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway. Curr Med Sci, 2020
  217. Improvement of Endothelial Dysfunction of Berberine in Atherosclerotic Mice and Mechanism Exploring through TMT-Based Proteomics. Oxid Med Cell Longev, 2020
  218. Effect of berberine on LPS-induced expression of NF-κB/MAPK signalling pathway and related inflammatory cytokines in porcine intestinal epithelial cells. Innate Immun, 2020
  219. Berberine improved intestinal barrier function by modulating the intestinal microbiota in blunt snout bream (Megalobrama amblycephala) under dietary high-fat and high-carbohydrate stress. Fish Shellfish Immunol, 2020
  220. Berberine inhibits free fatty acid and LPS-induced inflammation via modulating ER stress response in macrophages and hepatocytes. PLoS One, 2020
  221. Development and In Vitro and In Vivo Evaluation of Microspheres Containing Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate for the Oral Delivery of Berberine Hydrochloride. Molecules, 2020
  222. Berberine induces lipolysis in porcine adipocytes by activating the AMP‑activated protein kinase pathway. Mol Med Rep, 2020
  223. Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoE-/- Mice. Front Pharmacol, 2020
  224. Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels. Life Sci, 2020
  225. Development of a Novel Anti-Obesity Compound with Inhibiting Properties on the Lipid Accumulation in 3T3-L1 Adipocytes. Iran Biomed J, 2020
  226. Antihypertensive constituents in Sanoshashinto. J Nat Med, 2020
  227. Berberine ameliorates lipopolysaccharide‑induced inflammatory responses in mouse inner medullary collecting duct‑3 cells by downregulation of NF‑κB pathway. Mol Med Rep, 2020
  228. Protective efficacy of Tinospora sinensis against streptozotocin induced pancreatic islet cell injuries of diabetic rats and its correlation to its phytochemical profiles. J Ethnopharmacol, 2020
  229. Berberis lycium Royle fruit extract mitigates oxi-inflammatory stress by suppressing NF-κB/MAPK signalling cascade in activated macrophages and Treg proliferation in splenic lymphocytes. Inflammopharmacology, 2020
  230. Berberine Ameliorates Brain Inflammation in Poloxamer 407-Induced Hyperlipidemic Rats. Int Neurourol J, 2019
  231. Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice. Sci Rep, 2019
  232. Anti-Inflammatory Effects of Different Elution Fractions of Er-Miao-San on Acute Inflammation Induced by Carrageenan in Rat Paw Tissue. Med Sci Monit, 2019
  233. Berberine attenuates olanzapine induced-metabolic syndrome. J Pak Med Assoc, 2019
  234. Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats. Diabetes Metab Syndr Obes, 2019
  235. The gut microbiota modulator berberine ameliorates collagen-induced arthritis in rats by facilitating the generation of butyrate and adjusting the intestinal hypoxia and nitrate supply. FASEB J, 2019
  236. Dihydroberberine, a hydrogenated derivative of berberine firstly identified in Phellodendri Chinese Cortex, exerts anti-inflammatory effect via dual modulation of NF-κB and MAPK signaling pathways. Int Immunopharmacol, 2019
  237. Modulatory Effects of Berberine Chloride on Lipid Profile, Oxidant Status and Insulin Signaling Molecules in Streptozotocin Induced Diabetic Rats. Indian J Clin Biochem, 2019
  238. Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2β/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 β-cells. Int J Biol Sci, 2019
  239. Coptisine from Coptis chinensis blocks NLRP3 inflammasome activation by inhibiting caspase-1. Pharmacol Res, 2019
  240. Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice. Eur J Pharmacol, 2019
  241. Effects of berberine on the growth performance, antioxidative capacity and immune response to lipopolysaccharide challenge in broilers. Anim Sci J, 2019
  242. Quantification of Berberine in Berberis vulgaris L. Root Extract and Its Curative and Prophylactic Role in Cisplatin-Induced In Vivo Toxicity and In Vitro Cytotoxicity. Antioxidants (Basel), 2019
  243. Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice. Am J Transl Res, 2019
  244. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis. Biomed Pharmacother, 2019
  245. Berberine inhibits lipopolysaccharide-induced expression of inflammatory cytokines by suppressing TLR4-mediated NF-ĸB and MAPK signaling pathways in rumen epithelial cells of Holstein calves. J Dairy Res, 2019
  246. Antidiarrheal effects of a thermostable protein fraction obtained from the larvae of Musca domestica. Biomed Pharmacother, 2019
  247. Berberine Protects Glomerular Podocytes via Inhibiting Drp1-Mediated Mitochondrial Fission and Dysfunction. Theranostics, 2019
  248. Determination of berberine-upregulated endogenous short-chain fatty acids through derivatization by 2-bromoacetophenone. Anal Bioanal Chem, 2019
  249. Berberine attenuates sodium palmitate-induced lipid accumulation, oxidative stress and apoptosis in grass carp(Ctenopharyngodon idella)hepatocyte in vitro. Fish Shellfish Immunol, 2019
  250. Protective effect of surface-modified berberine nanoparticles against LPS-induced neurodegenerative changes: a preclinical study. Drug Deliv Transl Res, 2019
  251. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. FASEB J, 2019
  252. Pharmacokinetic-Pharmacodynamic Modeling for Coptisine Challenge of Inflammation in LPS-Stimulated Rats. Sci Rep, 2019
  253. Comparison of anti-inflammatory effects of berberine, and its natural oxidative and reduced derivatives from Rhizoma Coptidis in vitro and in vivo. Phytomedicine, 2019
  254. Jatrorrhizine reduces 5-HT and NE uptake via inhibition of uptake-2 transporters and produces antidepressant-like action in mice. Xenobiotica, 2019
  255. Berberine ameliorates lipopolysaccharide-induced learning and memory deficit in the rat: insights into underlying molecular mechanisms. Metab Brain Dis, 2019
  256. Identification of N-benzyltetrahydroisoquinolines as novel anti-neuroinflammatory agents. Bioorg Med Chem, 2018
  257. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. Biomed Pharmacother, 2018
  258. Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice. Nutr Diabetes, 2018
  259. Berberine modulates ASK1 signaling mediated through TLR4/TRAF2 via upregulation of miR-23a. Toxicol Appl Pharmacol, 2018
  260. Berberine Exerts a Protective Effect on Gut-Vascular Barrier via the Modulation of the Wnt/Beta-Catenin Signaling Pathway During Sepsis. Cell Physiol Biochem, 2018
  261. Novel skin penetrating berberine oleate complex capitalizing on hydrophobic ion pairing approach. Int J Pharm, 2018
  262. The protective effect of berberine against lipopolysaccharide-induced abortion by modulation of inflammatory/immune responses. Immunopharmacol Immunotoxicol, 2018
  263. Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats. Am J Physiol Heart Circ Physiol, 2018
  264. Berberine Protects against NEFA-Induced Impairment of Mitochondrial Respiratory Chain Function and Insulin Signaling in Bovine Hepatocytes. Int J Mol Sci, 2018
  265. Berberine Improves Cognitive Deficiency and Muscular Dysfunction via Activation of the AMPK/SIRT1/PGC-1a Pathway in Skeletal Muscle from Naturally Aging Rats. J Nutr Health Aging, 2018
  266. Dai-Zong-Fang, A Traditional Chinese Herbal Formula, Ameliorates Insulin Resistance in db/db Mice. Front Physiol, 2018
  267. Comparative pharmacokinetics and safety assessment of transdermal berberine and dihydroberberine. PLoS One, 2018
  268. Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. Exp Clin Endocrinol Diabetes, 2018
  269. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomed Pharmacother, 2018
  270. Inhibitory Effects of Endogenous Linoleic Acid and Glutaric Acid on the Renal Glucuronidation of Berberrubine in Mice and on Recombinant Human UGT1A7, 1A8, and 1A9. Mol Pharmacol, 2018
  271. Protective effect of Coptisine from Rhizoma Coptidis on LPS/D-GalN-induced acute liver failure in mice through up-regulating expression of miR-122. Biomed Pharmacother, 2018
  272. Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: Optimization and pharmacokinetics. Int J Pharm, 2018
  273. Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats. Lipids Health Dis, 2017
  274. Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats. Pharmacogn Mag, 2017
  275. Berberine ameliorates non-alcoholic steatohepatitis in ApoE-/- mice. Exp Ther Med, 2017
  276. Evaluation of anti-sepsis activity by compounds with high affinity to lipid a from HuanglianJiedu decoction. Immunopharmacol Immunotoxicol, 2017
  277. Berberine Inhibits Oxygen Consumption Rate Independent of Alteration in Cardiolipin Levels in H9c2 Cells. Lipids, 2017
  278. Berberine suppresses LPS-induced inflammation through modulating Sirt1/NF-κB signaling pathway in RAW264.7 cells. Int Immunopharmacol, 2017
  279. The protective effect of berberine hydrochloride on LPS‑induced osteoclastogenesis through inhibiting TRAF6‑Ca2+‑calcineurin‑NFATcl signaling pathway. Mol Med Rep, 2017
  280. The design and synthesis of a novel compound of berberine and baicalein that inhibits the efficacy of lipid accumulation in 3T3-L1 adipocytes. Bioorg Med Chem, 2017
  281. The protective effect of coptisine on experimental atherosclerosis ApoE-/- mice is mediated by MAPK/NF-κB-dependent pathway. Biomed Pharmacother, 2017
  282. The effects of berberine on a murine model of multiple sclerosis and the SPHK1/S1P signaling pathway. Biochem Biophys Res Commun, 2017
  283. Anti-inflammatory activity of coptisine free base in mice through inhibition of NF-κB and MAPK signaling pathways. Eur J Pharmacol, 2017
  284. The influence of essential oils from Xiang-Fu-Si-Wu Decoction on its non-volatile components and its application for pharmacokinetics in normal rats. J Chromatogr B Analyt Technol Biomed Life Sci, 2017
  285. Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. Mol Med Rep, 2017
  286. Berberine Alleviates Oxidative Stress in Islets of Diabetic Mice by Inhibiting miR-106b Expression and Up-Regulating SIRT1. J Cell Biochem, 2017
  287. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism, 2017
  288. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine, 2017
  289. [Effects of the Traditional Chinese Medicine berberine on antiatheroscloresis and antioxidant activities in hyperlipoidemic model rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2017
  290. Chemical profiles and pharmacological activities of Chang-Kang-Fang, a multi-herb Chinese medicinal formula, for treating irritable bowel syndrome. J Ethnopharmacol, 2017
  291. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord, 2017
  292. Berberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats. Front Pharmacol, 2017
  293. Protective effect of HwangRyunHaeDok-Tang water extract against chronic obstructive pulmonary disease induced by cigarette smoke and lipopolysaccharide in a mouse model. J Ethnopharmacol, 2017
  294. Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. Toxicol Appl Pharmacol, 2017
  295. Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE-/- mice. Int Immunopharmacol, 2017
  296. Pharmacokinetics and tissue distribution of coptisine in rats after oral administration by liquid chromatography-mass spectrometry. Biomed Chromatogr, 2017
  297. 13-Ethylberberine reduces HMGB1 release through AMPK activation in LPS-activated RAW264.7 cells and protects endotoxemic mice from organ damage. Biomed Pharmacother, 2017
  298. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Mol Pharmacol, 2017
  299. Berberine attenuates oxidative stress and hepatocytes apoptosis via protecting mitochondria in blunt snout bream Megalobrama amblycephala fed high-fat diets. Fish Physiol Biochem, 2017
  300. Berberine increases adipose triglyceride lipase in 3T3-L1 adipocytes through the AMPK pathway. Lipids Health Dis, 2016
  301. 13-Methylberberine, a berberine analogue with stronger anti-adipogenic effects on mouse 3T3-L1 cells. Sci Rep, 2016
  302. Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPKα-SREBP Pathway in 3T3-L1 Cells. Int J Mol Sci, 2016
  303. Berberine activates peroxisome proliferator-activated receptor gamma to increase atherosclerotic plaque stability in Apoe-/- mice with hyperhomocysteinemia. J Diabetes Investig, 2016
  304. Dose-response effect of berberine on bile acid profile and gut microbiota in mice. BMC Complement Altern Med, 2016
  305. In Vivo Interrelationship between Insulin Resistance and Interferon Gamma Production: Protective and Therapeutic Effect of Berberine. Evid Based Complement Alternat Med, 2016
  306. 13-Methylberberine reduces HMGB1 release in LPS-activated RAW264.7 cells and increases the survival of septic mice through AMPK/P38 MAPK activation. Int Immunopharmacol, 2016
  307. Evaluation of Anthelmintic Activity and Composition of Pumpkin (Cucurbita pepo L.) Seed Extracts-In Vitro and in Vivo Studies. Int J Mol Sci, 2016
  308. Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model. Mol Med Rep, 2016
  309. Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. J Transl Med, 2016
  310. Functional study of the upregulation of miRNA-27a and miRNA-27b in 3T3-L1 cells in response to berberine. Mol Med Rep, 2016
  311. Endothelium-independent vasorelaxant effect of a Berberis orthobotrys root extract via inhibition of phosphodiesterases in the porcine coronary artery. Phytomedicine, 2016
  312. Renoprotective effect of berberine via regulating the PGE2 -EP1-Gαq-Ca(2+) signalling pathway in glomerular mesangial cells of diabetic rats. J Cell Mol Med, 2016
  313. Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice. Drug Dev Res, 2016
  314. The effective components of Huanglian Jiedu Decoction against sepsis evaluated by a lipid A-based affinity biosensor. J Ethnopharmacol, 2016
  315. Protective effect of berberine on doxorubicin‑induced acute hepatorenal toxicity in rats. Mol Med Rep, 2016
  316. [Establish and use of an epilepsy model in larval zebrafish]. Yao Xue Xue Bao, 2016
  317. Coptisine from Coptis chinensis inhibits production of inflammatory mediators in lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells. Eur J Pharmacol, 2016
  318. Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway. PLoS One, 2016
  319. Anti-inflammatory effects of three kinds of traditional Mongolian medicine monomer and its combination on LPS-stimulated RAW264.7 macrophages. Eur Rev Med Pharmacol Sci, 2016
  320. Pharmacological Effect of Berberine Chloride in Propyl Thiouracil Induced Thyroidal Dysfunction - A Time Bound Study in Female Rats. Recent Pat Drug Deliv Formul, 2016
  321. Pretreatment of rats with increased bioavailable berberine attenuates cerebral ischemia-reperfusion injury via down regulation of adenosine-5'monophosphate kinase activity. Eur J Pharmacol, 2016
  322. Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity. Sci Rep, 2016
  323. Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp Ther Med, 2016
  324. Metabolomics Study of Type 2 Diabetes Mellitus and the AntiDiabetic Effect of Berberine in Zucker Diabetic Fatty Rats Using Uplc-ESI-Hdms. Phytother Res, 2016
  325. Inhibitory effects of compounds isolated from the dried branches and leaves of murta (Myrceugenia euosma) on lipid accumulation in 3T3-L1 cells. J Nat Med, 2016
  326. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Sci Rep, 2016
  327. Neuroprotective effect of berberine is mediated by MAPK signaling pathway in experimental diabetic neuropathy in rats. Eur J Pharmacol, 2016
  328. Hypolipidemic Effects of Alkaloids from Rhizoma Coptidis in Diet-Induced Hyperlipidemic Hamsters. Planta Med, 2016
  329. Berberine Pretreatment Confers Cardioprotection Against Ischemia-Reperfusion Injury in a Rat Model of Type 2 Diabetes. J Cardiovasc Pharmacol Ther, 2016
  330. Berberine treatment attenuates the palmitate-mediated inhibition of glucose uptake and consumption through increased 1,2,3-triacyl-sn-glycerol synthesis and accumulation in H9c2 cardiomyocytes. Biochim Biophys Acta, 2016
  331. Epiberberine reduces serum cholesterol in diet-induced dyslipidemia Syrian golden hamsters via network pathways involving cholesterol metabolism. Eur J Pharmacol, 2016
  332. Molecular characterization of carnitine palmitoyltransferase IA in Megalobrama amblycephala and effects on its expression of feeding status and dietary lipid and berberine. Comp Biochem Physiol B Biochem Mol Biol, 2016
  333. Effects of berberine and cinnamic acid on palmitic acid-induced intracellular triglyceride accumulation in NIT-1 pancreatic β cells. Chin J Integr Med, 2016
  334. [Pharmacokinetic and pharmacodynamic characteristics of berberine and jateorhizine in Coptidis Rhizoma powder and their monomeric compounds in type 2 diabetic rats]. Zhongguo Zhong Yao Za Zhi, 2015
  335. Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses. J Neuroimmunol, 2015
  336. Effects of berberine and pomegranate seed oil on plasma phospholipid metabolites associated with risks of type 2 diabetes mellitus by U-HPLC/Q-TOF-MS. J Chromatogr B Analyt Technol Biomed Life Sci, 2015
  337. Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats. Evid Based Complement Alternat Med, 2015
  338. Berberine treatment prevents cardiac dysfunction and remodeling through activation of 5'-adenosine monophosphate-activated protein kinase in type 2 diabetic rats and in palmitate-induced hypertrophic H9c2 cells. Eur J Pharmacol, 2015
  339. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep, 2015
  340. Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db/db mice. Int J Nanomedicine, 2015
  341. Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med, 2015
  342. Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds. Lipids Health Dis, 2015
  343. Berberine reverses abnormal expression of L-type pyruvate kinase by DNA demethylation and histone acetylation in the livers of the non-alcoholic fatty disease rat. Int J Clin Exp Med, 2015
  344. Increased Oxidative Stress in Cultured 3T3-L1 Cells was Attenuated by Berberine Treatment. Nat Prod Commun, 2015
  345. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J Gastroenterol, 2015
  346. Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters. Fitoterapia, 2015
  347. [Intervention of berberine on lipid deposition in liver cells of non-alcoholic fatty liver disease rats induced by high fat diet]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2015
  348. Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. J Transl Med, 2015
  349. Simultaneous quantification and antiatherosclerosis effect of the traditional Korean medicine, Hwangryunhaedok-tang. BMC Complement Altern Med, 2015
  350. Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice. Evid Based Complement Alternat Med, 2015
  351. Preparation, characterization and in vivo studies of amorphous solid dispersion of berberine with hydrogenated phosphatidylcholine. Eur J Pharm Sci, 2015
  352. Berberine reduces Toll-like receptor-mediated macrophage migration by suppression of Src enhancement. Eur J Pharmacol, 2015
  353. Berberine regulates melanin synthesis by activating PI3K/AKT, ERK and GSK3β in B16F10 melanoma cells. Int J Mol Med, 2015
  354. Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. Biomed Res Int, 2015
  355. The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters. Lipids, 2015
  356. Berberine hydrochloride attenuates lipopolysaccharide-induced endometritis in mice by suppressing activation of NF-κB signal pathway. Int Immunopharmacol, 2015
  357. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. J Pharmacol Exp Ther, 2015
  358. Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. Chin J Integr Med, 2015
  359. Ultrahigh-performance liquid chromatography/tandem mass spectrometry method for evaluating enzyme activity and screening inhibitors of cyclooxygenase-2. Rapid Commun Mass Spectrom, 2014
  360. Prevention of peroxidation of cardiolipin liposomes by quinol-based antioxidants. Biochemistry (Mosc), 2014
  361. Berberine protects liver from ethanol-induced oxidative stress and steatosis in mice. Food Chem Toxicol, 2014
  362. Potential synergistic effects of Chinese herbal prescription FTZ components detected in blood towards hepatic lipid-modulating targets. Complement Ther Med, 2014
  363. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice. J Transl Med, 2014
  364. Shensong Yangxin Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-β1/Smad signaling. J Ethnopharmacol, 2014
  365. Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine. Asian Pac J Trop Biomed, 2014
  366. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism, 2014
  367. The antihypercholesterolemic effect of jatrorrhizine isolated from Rhizoma Coptidis. Phytomedicine, 2014
  368. Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages. Int J Mol Med, 2014
  369. Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats. J Transl Med, 2014
  370. Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor. BMC Complement Altern Med, 2014
  371. The anti-inflammatory potential of Cortex Phellodendron in vivo and in vitro: down-regulation of NO and iNOS through suppression of NF-κB and MAPK activation. Int Immunopharmacol, 2014
  372. Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy. Mol Biol Rep, 2014
  373. Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO₂: preparation, characterization and in vivo studies. Int J Pharm, 2014
  374. Hypolipidemic effect of the Chinese polyherbal Huanglian Jiedu decoction in type 2 diabetic rats and its possible mechanism. Phytomedicine, 2014
  375. The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice. Antioxid Redox Signal, 2014
  376. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. Int J Nanomedicine, 2013
  377. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One, 2013
  378. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci, 2013
  379. Antinociceptive effect of berberine on visceral hypersensitivity in rats. World J Gastroenterol, 2013
  380. Berberine's effect on periodontal tissue degradation by matrix metalloproteinases: an in vitro and in vivo experiment. Phytomedicine, 2013
  381. [The effect of berberine administration of evaluation of the functional state of rat liver after ligation of common bile duct]. Biomed Khim, 2013
  382. The anti-diabetic effects and pharmacokinetic profiles of berberine in mice treated with Jiao-Tai-Wan and its compatibility. Phytomedicine, 2013
  383. Berberine ameliorates chronic kidney injury caused by atherosclerotic renovascular disease through the suppression of NFκB signaling pathway in rats. PLoS One, 2013
  384. Inhibitory effects of berberine on lipopolysaccharide-induced inducible nitric oxide synthase and the high-mobility group box 1 release in macrophages. Biochem Biophys Res Commun, 2013
  385. Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Rep, 2013
  386. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. Arterioscler Thromb Vasc Biol, 2013
  387. Enhancement by sodium caprate and sodium deoxycholate of the gastrointestinal absorption of berberine chloride in rats. Drug Dev Ind Pharm, 2013
  388. [Effect of banxia xiexin decoction on leptin and endothelin-1 of gastric ulcer rat and the optimal combination screening of active components]. Zhong Yao Cai, 2012
  389. Yohimbine enhances protection of berberine against LPS-induced mouse lethality through multiple mechanisms. PLoS One, 2012
  390. A preliminary investigation of the mechanisms underlying the effect of berberine in preventing high-fat diet-induced insulin resistance in rats. J Physiol Pharmacol, 2012
  391. Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep, 2012
  392. Berberine reduces leukocyte adhesion to LPS-stimulated endothelial cells and VCAM-1 expression both in vivo and in vitro. Int J Immunopathol Pharmacol, 2012
  393. The different inhibitory effects of Huang-Lian-Jie-Du-Tang on cyclooxygenase 2 and 5-lipoxygenase. J Ethnopharmacol, 2012
  394. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One, 2012
  395. The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. Lipids Health Dis, 2012
  396. Anti-atherosclerotic action of Ger-Gen-Chyn-Lian-Tang and AMPK-dependent lipid lowering effect in hepatocytes. J Ethnopharmacol, 2012
  397. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine, 2012
  398. A combination of metabolomics and metallomics studies of urine and serum from hypercholesterolaemic rats after berberine injection. Anal Bioanal Chem, 2012
  399. Modulations of cytochrome P450 expression in diabetic mice by berberine. Chem Biol Interact, 2012
  400. Berberine inhibits lipopolysaccharide- and polyethylene particle-induced mouse calvarial osteolysis in vivo. J Surg Res, 2012
  401. Berberine ameliorates COX-2 expression in rat small intestinal mucosa partially through PPARγ pathway during acute endotoxemia. Int Immunopharmacol, 2012
  402. Increased systemic exposure to rhizoma coptidis alkaloids in lipopolysaccharide-pretreated rats attributable to enhanced intestinal absorption. Drug Metab Dispos, 2012
  403. Anti-diabetic effects of TongGuanWan, a Chinese traditional herbal formula, in C57BL/KsJ-db/db mice. Planta Med, 2012
  404. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells. J Nat Med, 2012
  405. Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endocrinol, 2011
  406. Alkaloids from Chelidonium majus and their inhibitory effects on LPS-induced NO production in RAW264.7 cells. Bioorg Med Chem Lett, 2011
  407. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One, 2011
  408. Berberine protects against lipopolysaccharide-induced intestinal injury in mice via alpha 2 adrenoceptor-independent mechanisms. Acta Pharmacol Sin, 2011
  409. Lipopolysaccharide increased the acute toxicity of the Rhizoma coptidis extract in mice by increasing the systemic exposure to Rhizoma coptidis alkaloids. J Ethnopharmacol, 2011
  410. Dose-response of berberine on hepatic cytochromes P450 mRNA expression and activities in mice. J Ethnopharmacol, 2011
  411. Berberine down-regulates the Th1/Th2 cytokine gene expression ratio in mouse primary splenocytes in the absence or presence of lipopolysaccharide in a preventive manner. Int Immunopharmacol, 2011
  412. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver. Eur J Pharmacol, 2011
  413. CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica, 2011
  414. Berberine, an isoquinoline alkaloid in herbal plants, protects pancreatic islets and serum lipids in nonobese diabetic mice. J Agric Food Chem, 2011
  415. Berberine hydrochloride attenuates cyclooxygenase-2 expression in rat small intestinal mucosa during acute endotoxemia. Fitoterapia, 2011
  416. The inhibitory activities of the components of Huang-Lian-Jie-Du-Tang (HLJDT) on eicosanoid generation via lipoxygenase pathway. J Ethnopharmacol, 2011
  417. Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. Eur J Pharmacol, 2011
  418. [Changes of metabolic indices caused by berberin and extract, obtained from the bark of Phellodendron lavalei, introduced in subtropic regions of Georgia, in streptozotocin induced diabetic rats]. Georgian Med News, 2011
  419. Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats. Chin J Integr Med, 2011
  420. Anti-inflammatory effects of Huang-Lian-Jie-Du decoction, its two fractions and four typical compounds. J Ethnopharmacol, 2011
  421. Berberine attenuates lipopolysaccharide-induced impairments of intestinal glutamine transport and glutaminase activity in rat. Fitoterapia, 2011
  422. Evidence for the complementary and synergistic effects of the three-alkaloid combination regimen containing berberine, hypaconitine and skimmianine on the ulcerative colitis rats induced by trinitrobenzene-sulfonic acid. Eur J Pharmacol, 2011
  423. Preventive effect of Coptis chinensis and berberine on intestinal injury in rats challenged with lipopolysaccharides. Food Chem Toxicol, 2011
  424. Pretreatment with berberine and yohimbine protects against LPS-induced myocardial dysfunction via inhibition of cardiac I-[kappa]B[alpha] phosphorylation and apoptosis in mice. Shock, 2011
  425. Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver. Fitoterapia, 2011
  426. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-κB signaling pathway. Mol Cell Endocrinol, 2011
  427. The protective effect of berberine on β-cell lipoapoptosis. J Endocrinol Invest, 2011
  428. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism, 2011
  429. Hepatoprotective effects of berberine on carbon tetrachloride-induced acute hepatotoxicity in rats. Chin Med, 2010
  430. [Effects of berberine on serum levels of inflammatory factors and inflammatory signaling pathway in obese mice induced by high fat diet]. Zhongguo Zhong Yao Za Zhi, 2010
  431. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine. Bioorg Med Chem, 2010
  432. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem, 2010
  433. Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm, 2010
  434. RETRACTED: Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK-S1P signaling pathway. Arch Biochem Biophys, 2010
  435. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res, 2010
  436. Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine. AAPS PharmSciTech, 2010
  437. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 2010
  438. Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. Atherosclerosis, 2010
  439. [8-hydroxy-dihydroberberine ameliorated insulin resistance induced by high FFA and high glucose in 3T3-L1 adipocytes]. Yao Xue Xue Bao, 2009
  440. Chinese herbal medicinal ingredients inhibit secretion of IL-6, IL-8, E-selectin and TXB2 in LPS-induced rat intestinal microvascular endothelial cells. Immunopharmacol Immunotoxicol, 2009
  441. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. Eur J Pharmacol, 2009
  442. Analgesic and anti-inflammatory activities of ethanol root extract of Mahonia oiwakensis in mice. J Ethnopharmacol, 2009
  443. Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage. Cell Res, 2009
  444. Effective constituents in Xiexin Decoction for anti-inflammation. J Ethnopharmacol, 2009
  445. Pulsatilla decoction and its active ingredients inhibit secretion of NO, ET-1, TNF-alpha, and IL-1 alpha in LPS-induced rat intestinal microvascular endothelial cells. Cell Biochem Funct, 2009
  446. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations. Endocrinology, 2009
  447. Effect of Lianshu preparation on lipopolysaccharide-induced diarrhea in rats. World J Gastroenterol, 2009
  448. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol, 2009
  449. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009
  450. Berberine exerts neuroprotective actions against in vitro ischemia-induced neuronal cell damage in organotypic hippocampal slice cultures: involvement of B-cell lymphoma 2 phosphorylation suppression. Biol Pharm Bull, 2009
  451. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res, 2008
  452. Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J (Engl), 2008
  453. Comparison of the antidiabetic activity of Berberis lyceum root extract and berberine in alloxan-induced diabetic rats. Phytother Res, 2008
  454. Antiinflammatory effect of the ethanol extract of Berberis koreana in a gerbil model of cerebral ischemia/reperfusion. Phytother Res, 2008
  455. Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Toxicol Sci, 2008
  456. Effect of berberine on expression of hepatocyte nuclear factor-4alpha in rats with fructose-induced insulin resistance. J Huazhong Univ Sci Technolog Med Sci, 2008
  457. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull, 2008
  458. Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology, 2008
  459. Decreased secretory transport of a quarternary ammonium, TBuMA, across LLC-PK1 cells by the anionic kidney extract. Arch Pharm Res, 2008
  460. Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats. Atherosclerosis, 2008
  461. Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice. Shock, 2008
  462. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 2008
  463. Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. World J Gastroenterol, 2008
  464. Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors. Clin Exp Pharmacol Physiol, 2008
  465. [Molecular mechanism of berberine in improving insulin resistance induced by free fatty acid through inhibiting nuclear trascription factor-kappaB p65 in 3T3-L1 adipocytes]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2007
  466. Synthesis and antimicrobial activity of 8-alkylberberine derivatives with a long aliphatic chain. Planta Med, 2007
  467. Polygonum cuspidatum, compared with baicalin and berberine, inhibits inducible nitric oxide synthase and cyclooxygenase-2 gene expressions in RAW 264.7 macrophages. Vascul Pharmacol, 2007
  468. Effect of berberine on monocyte chemotactic protein-1 and cytokine-induced neutrophil chemoattractant-1 expression in rat lipopolysaccharide-induced uveitis. Ophthalmic Res, 2007
  469. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci, 2006
  470. Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice. Acta Pharmacol Sin, 2006
  471. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem Biophys Res Commun, 2006
  472. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 2006
  473. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol, 2006
  474. [Effects of huanglian jiedu decoction on leptin and resistin in insulin resistive rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2006
  475. Effects of neutral sulfate berberine on LPS-induced cardiomyocyte TNF-alpha secretion, abnormal calcium cycling, and cardiac dysfunction in rats. Acta Pharmacol Sin, 2006
  476. Berberine inhibits the production of lysophosphatidylcholine-induced reactive oxygen species and the ERK1/2 pathway in vascular smooth muscle cells. Mol Cells, 2005
  477. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull, 2005
  478. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin, 2004
  479. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett, 2004
  480. Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF-alpha, iNOS, and IL-12 production in LPS-stimulated macrophages. Life Sci, 2003
  481. Effects of topical instillation of traditional herbal medicines, herbal extracts, and their components on prostaglandin E2-induced aqueous flare elevation in pigmented rabbits. Jpn J Ophthalmol, 2003
  482. Effect of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells. Thromb Res, 2002
  483. Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid. Biochem Pharmacol, 2002
  484. Enhanced tumor necrosis factor-alpha-specific and decreased interleukin-10-specific immune responses to LPS during the third trimester of pregnancy in mice. J Endocrinol, 2001
  485. Plasma CPU-86017 concentrations regarding suppression of ouabain-induced cardiac arrhythmias and decrease of heart rate in guinea pigs. Acta Pharmacol Sin, 2000
  486. Antiphotooxidative activity of protoberberines derived from Coptis japonica makino in the chlorophyll-sensitized photooxidation of oil. J Agric Food Chem, 2000
  487. Effects of San'o-shashin-to on the antioxidative mechanism in spontaneous familial hypercholesterolaemic rabbits. Pharmacol Res, 2000
  488. Relationship between the antidiarrhoeal effects of Hange-Shashin-To and its active components. Phytother Res, 1999
  489. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull, 1999
  490. Prostaglandin production by guinea-pig endometrial cells: effects of caffeine and other modulators of intracellular calcium. Prostaglandins Leukot Essent Fatty Acids, 1997
  491. [Experimental study on berberin raised insulin sensitivity in insulin resistance rat models]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 1997
  492. (-)-Stepholidine enhances K+ depolarization-induced activation of synaptosomal tyrosine 3-monooxygenase from rat striatum. Zhongguo Yao Li Xue Bao, 1997
  493. [Preparation of oral berberine bisulfate liposomes]. Zhongguo Zhong Yao Za Zhi, 1995
  494. Modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by selective alpha- and beta-adrenergic drugs in mice. J Neuroimmunol, 1995
  495. Differential effect of selective block of alpha 2-adrenoreceptors on plasma levels of tumour necrosis factor-alpha, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J Endocrinol, 1995
  496. [Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion]. Yao Xue Xue Bao, 1995
  497. The antipsoriatic Mahonia aquifolium and its active constituents; I. Pro- and antioxidant properties and inhibition of 5-lipoxygenase. Planta Med, 1994
  498. Inhibitory effect of tetrahydroberberine on platelet aggregation and thrombosis. Zhongguo Yao Li Xue Bao, 1994
  499. Proliferation of mast cells in the smooth muscle of denervated rat jejunum. J Auton Nerv Syst, 1993
  500. Effect of some alkaloids, flavonoids and triterpenoids, contents of Japanese-Chinese traditional herbal medicines, on the lipogenesis of sebaceous glands. Skin Pharmacol, 1993
  501. Studies on the antinephritic effect of plant components (4): Reduction of protein excretion by berberine and coptisine in rats with original-type anti-GBM nephritis. Jpn J Pharmacol, 1992
  502. [Effects of berberine on synthesis of platelet TXA2 and plasma PGI2 in rabbits]. Zhongguo Yao Li Xue Bao, 1991
  503. [Mechanism of protective effects of ouren-gedoku-to and san'ou-syashin-to on the gastric mucosa]. Nihon Yakurigaku Zasshi, 1991
  504. Mast cells in the guinea pig superior cervical ganglion: a functional and histological assessment. J Auton Nerv Syst, 1990
  505. Effect of shosaikoto, daisaikoto and sannoshashinto (traditional Japanese and Chinese medicines) on experimental hyperlipidemia in rats. J Ethnopharmacol, 1989
  506. Effects of berberine on basal and secretagogue-modified ion transport in the rabbit ileum in vitro. J Pediatr Gastroenterol Nutr, 1987
  507. [Studies on the hypoglycemic effect of Coptis chinensis and berberine]. Yao Xue Xue Bao, 1986
  508. Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology, 1986
  509. The dynamics of mast cell secretion mediated by IgE or polyamines. Agents Actions, 1984
  510. The dynamics of mast cell secretion studied by vital berberine staining. Agents Actions, 1984
  511. Activation of peritoneal macrophages by berberine-type alkaloids in terms of induction of cytostatic activity. Int J Immunopharmacol, 1984
  512. Mast cell secretion. Rapid sealing of exocytotic cavities demonstrated by cytofluorometry. Int Arch Allergy Appl Immunol, 1984
  513. Biochemical effects of berberine. Biochem Pharmacol, 1979
  514. Further studies on pharmacology of berberine. Indian J Physiol Pharmacol, 1978
Lab studies 397
  1. Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study. J Clin Med, 2026
  2. Hypoxia-Responsive Co-Loaded Liposomal Drug Delivery System for the Treatment of Breast Cancer. Curr Cancer Drug Targets, 2026
  3. Alleviation of high-lipid diet-induced hepatic steatosis and intestinal injury by berberine in yellow catfish (Pelteobagrus fulvidraco) is associated with modulation of the intestinal microbiota and the FXR pathway. Comp Biochem Physiol Part D Genomics Proteomics, 2026
  4. Unraveling berberine's multi-target mechanism in combating early-stage masld: a network pharmacology and in vitro study. Cytotechnology, 2026
  5. Discovery, synthesis, and biological evaluation of N,N'-diacyl-m-phenylenediamine derivatives as novel PCSK9 small-molecule inhibitors. Eur J Med Chem, 2026
  6. TRIM29-dependent AKR1B10 degradation ameliorates MASH. Sci Adv, 2026
  7. Sex Matters in Precision Lipid Management: Implications Beyond LDL Cholesterol. JACC Asia, 2026
  8. Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials. JACC Asia, 2026
  9. Efficacy and tolerability of nutraceuticals and phytotherapics for antipsychotic-induced weight gain in schizophrenia spectrum disorders: Systematic review and meta-analysis. Pharmacopsychiatry, 2026
  10. Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial. Diabetol Metab Syndr, 2026
  11. Effects of Berberine on Growth Performance, Serum Biochemical Parameters, Hepatic Antioxidant Capacity and Metabolism in Monopterus albus. Life (Basel), 2026
  12. Antimicrobial photodynamic inactivation of Pseudomonas aeruginosa biofilms by a multifunctional triple combination of natural photosensitisers, gentamicin, and colistin. Microb Pathog, 2026
  13. Berberine Regulates Hepatic Fatty Acid Metabolism via AMPK/SIRT1/PGC-1α Pathway. Chin J Integr Med, 2026
  14. Liposomal design and shear shielding of colloidal matrices control drug release. Int J Pharm, 2026
  15. Berberine attenuates liver damage, hematological, biochemical, and molecular changes induced by cadmium chloride via inflammation, apoptosis, and oxidative stress suppression. Tissue Cell, 2026
  16. Tianjing Zelan formula improves polycystic ovary syndrome by regulating steroid biosynthesis and arachidonic acid metabolism. J Ethnopharmacol, 2026
  17. Investigating the mechanism of berberine in inhibiting periodontitis progression using machine learning, molecular docking, and experimental validation. Arch Oral Biol, 2026
  18. Zhimu-Huangbai codecoction for the treatment of type II diabetes mellitus through its self-assembling nanoparticles. Chin Med, 2026
  19. Anticancer, Anti-Inflammatory, and Acute Toxicological Evaluation of the Novel Berberine Derivative BN-7. Chem Biodivers, 2026
  20. Antifungal chitosan-based lipoic acid/berberine sulfate composite film for suppressing Penicillium italicum and preserving mandarin fruit. Int J Biol Macromol, 2026
  21. Therapeutic Mechanisms of Sanhuang Xiexin Decoction in Severe Acute Pancreatitis-Associated Lung Injury: Modulation of the NF-κB Signaling Pathway. Pancreas, 2026
  22. Berberine-cinnamic acid co-crystal effect in ameliorating hyperlipidemia might be regulated through the PI3K/AKT/mTOR/SREBP-1 signaling pathway. FEBS Open Bio, 2026
  23. Unveiling the binding details of berberine mid-chain fatty acid salts on lysozyme: Multi-spectroscopy and molecular docking. Spectrochim Acta A Mol Biomol Spectrosc, 2026
  24. The Effects of Several Natural Protoberberine Alkaloids and Cinnamic Acid Derivatives Used for Traditional Medicine on the Membrane Boundary Potential and Lipid Packing Stress. Int J Mol Sci, 2025
  25. Berberine ameliorates high-fat diet-induced metabolic disorders through promoting gut Akkermansia and modulating bile acid metabolism. Chin Med, 2025
  26. Overcoming Solubility Challenges: Micronization of Berberine Using the GAS Antisolvent Technique. ACS Omega, 2025
  27. Network-based pharmacological study of the mechanism of Baitouweng decoction in the treatment of ulcerative colitis through the NF-κB pathway. Medicine (Baltimore), 2025
  28. Synergistic potential of Berberine and Wogonin improved adipose inflammation and insulin resistance associated with obesity through HIF-α axis. Chin Med, 2025
  29. Berberine: A Bitter Phytochemical With Diversely Sweet Therapeutic Properties. Nutr Rev, 2025
  30. Functional divergence of NCS homologs in the PR10 family drives tissue-specific berberine accumulation in Coptis chinensis Franch. Plant Physiol Biochem, 2025
  31. Berberine Inhibits Acne-Related Lipid Secretion and Inflammation by Regulating the hsa-miR-3150a-3p/TP53 Pathway. J Inflamm Res, 2025
  32. Mapping Berberine distribution in liposomes: the role of drug-phospholipid interactions in localization and release. Int J Pharm, 2025
  33. Single-cell RNA sequencing reveals Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131-TNF signaling pathway-mediated differentiation of immunosuppressive dendritic cells. Acta Pharm Sin B, 2025
  34. Lung Epithelial Cell Membrane-Camouflaged ROS-Activatable Berberine Nanoparticles for Targeted Treatment in Acute Lung Injury. Int J Nanomedicine, 2025
  35. A 30-Day Randomized Crossover Human Study on the Safety and Tolerability of a New Micellar Berberine Formulation with Improved Bioavailability. Metabolites, 2025
  36. Borderline hyperlipidemia: preventive supplementation with berberine phospholipids to prevent early atherosclerosis evolution. Minerva Med, 2025
  37. Berberine alleviates atherosclerosis by modulating autophagy and inflammation through the RAGE-NF-κB pathway. Front Pharmacol, 2025
  38. The key active ingredients identification and pharmacological mechanism investigation of extract of ethyl acetate from Er Miao San aganist rheumatoid arthritis. Fitoterapia, 2025
  39. Berberine Attenuates Nonalcoholic Hepatic Steatosis by Regulating Lipid Droplet-Associated Proteins: In Vivo, In Vitro and Molecular Evidence. J Cell Mol Med, 2025
  40. Jatrorrhizine alleviates cytokine storm secondary lung injury via regulating CD39-dominant purinergic braking and downstream NLRP3 inflammasome. Phytother Res, 2025
  41. Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics. Nat Commun, 2025
  42. Role of activating transcription factor 3 as a mediator of the protective effects of berberine against lipopolysaccharide-stimulated SW982 cells and in rheumatoid arthritis animal models. Toxicol Appl Pharmacol, 2025
  43. The Potential Role of Intestinal Microbiota on the Intestine-Protective and Lipid-Lowering Effects of Berberine in Zebrafish (Danio rerio) Under High-Lipid Stress. Metabolites, 2025
  44. Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies. Front Nutr, 2025
  45. Comprehensive pharmacokinetic profiling and molecular docking analysis of natural bioactive compounds targeting oncogenic biomarkers in breast cancer. Sci Rep, 2025
  46. Mechanistic insights into alkaloid-based inhibition of squalene epoxidase: A combined in silico and experimental approach for targeting cholesterol biosynthesis. Int J Biol Macromol, 2025
  47. Tetrahydroberberrubine improves hyperlipidemia by activating the AMPK/SREBP2/PCSK9/LDL receptor signaling pathway. Eur J Pharmacol, 2025
  48. Engineering of redox-triggered polymeric lipid hybrid nanocarriers for selective drug delivery to cancer cells. J Mater Chem B, 2025
  49. Coptisine inhibits lipid accumulation in high glucose- and palmitic acid-induced HK-2 cells by regulating the AMPK/ACC/CPT-1 signaling pathway. Naunyn Schmiedebergs Arch Pharmacol, 2025
  50. Does EFSA statement on Monacolin content of nutraceutical combinations impair their lipid lowering effect? The LopiGLIK experience. Clin Diabetes Endocrinol, 2024
  51. Physically crosslinked chitosan/αβ-glycerophosphate hydrogels enhanced by surface-modified cyclodextrin: An efficient strategy for controlled drug release. Int J Biol Macromol, 2024
  52. Berberine safeguards sepsis-triggered acute gastric damage and inhibits pyroptosis in gastric epithelial cells via suppressing the ubiquitination and degradation of Nrf2. Kaohsiung J Med Sci, 2024
  53. Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6/IL-6R axis. J Transl Med, 2024
  54. Membrane Composition Allows the Optimization of Berberine Encapsulation in Liposomes. Mol Pharm, 2024
  55. Causal relationship between fertility nutrients supplementation and PCOS risk: a Mendelian randomization study. Front Endocrinol (Lausanne), 2024
  56. Butyrate Increases Heparin Synthesis and Storage in Human Mast Cells. Cells, 2024
  57. Exploration of Berberine Against Ulcerative Colitis via TLR4/NF-κB/HIF-1α Pathway by Bioinformatics and Experimental Validation. Drug Des Devel Ther, 2024
  58. Berberine as a novel ACSL4 inhibitor to suppress endothelial ferroptosis and atherosclerosis. Biomed Pharmacother, 2024
  59. Biosurfactant-amphiphilized hyaluronic acid: A dual self-assembly anticancer nanoconjugate and drug vector for synergistic chemotherapy. Int J Biol Macromol, 2024
  60. Amphiphilic hydroxyethyl starch-based nanoparticles carrying linoleic acid modified berberine inhibit the expression of krasv12 oncogene in zebrafish. Biomed Pharmacother, 2024
  61. Effects of Berberine on Lipid Metabolism, Antioxidant Status, and Immune Response in Liver of Tilapia (Oreochromis niloticus) under a High-Fat Diet Feeding. Antioxidants (Basel), 2024
  62. The Lipid-Lowering Efficacy of a Nutraceutical Combination Including Leucoselect Phytosome, Red Yeast Rice, Policosanol and Folic Acid in Dyslipidaemia Patients: Real-World Insights. Pharmaceuticals (Basel), 2024
  63. The Supplementation of Berberine in High-Carbohydrate Diets Improves Glucose Metabolism of Tilapia (Oreochromis niloticus) via Transcriptome, Bile Acid Synthesis Gene Expression and Intestinal Flora. Animals (Basel), 2024
  64. Lipids Extracted from Mycobacterial Membrane and Enveloped PLGA Nanoparticles for Encapsulating Antibacterial Drugs Elicit Synergistic Antimicrobial Response against Mycobacteria. Mol Pharm, 2024
  65. Berberine alleviates inflammation in polycystic ovary syndrome by inhibiting hyaluronan synthase 2 expression. Phytomedicine, 2024
  66. Naturally occurring small molecules with dual effect upon inflammatory signaling pathways and endoplasmic reticulum stress response. J Physiol Biochem, 2024
  67. Combination drug therapy by herbal nanomedicine prevent multidrug resistance protein 1: promote apoptosis in Lung Carcinoma. J Appl Biomater Funct Mater, 2024
  68. Avocado-derived extracellular vesicles loaded with ginkgetin and berberine prevent inflammation and macrophage foam cell formation. J Cell Mol Med, 2024
  69. Cost-effectiveness of dietary supplement ingredients versus generic statins for LDL reduction. Explor Res Clin Soc Pharm, 2024
  70. Cationic Vitamin E-TPGS Mixed Micelles of Berberine to Neutralize Doxorubicin-Induced Cardiotoxicity via Amelioration of Mitochondrial Dysfunction and Impeding Apoptosis. Molecules, 2024
  71. The Antioxidant and Hepatoprotective Potential of Berberine and Silymarin on Acetaminophen Induced Toxicity in Cyprinus carpio L. Animals (Basel), 2024
  72. Curcumin and Berberine Arrest Maturation and Activation of Dendritic Cells Derived from Lupus Erythematosus Patients. Curr Mol Pharmacol, 2024
  73. Comparison between hangeshashinto and dexamethasone for IL-1α and β-defensin 1 production by human oral keratinocytes. J Oral Biosci, 2024
  74. Effect of the Pulsatilla decoction n-butanol extract on vulvovaginal candidiasis caused by Candida glabrata and on its virulence factors. Fitoterapia, 2024
  75. Berberine promotes lacteal junction zippering and ameliorates diet-induced obesity through the RhoA/ROCK signaling pathway. Phytomedicine, 2024
  76. Huang-Lian-Jie-Du decoction drug-containing serum inhibits IL-1β secretion from D-glucose and PA induced BV2 cells via autophagy/NLRP3 signaling. J Ethnopharmacol, 2024
  77. Borderline hyperlipidemia preventive management with Berberine PL in asymptomatic prevention of early atherosclerosis. Minerva Gastroenterol (Torino), 2024
  78. Annickia affinis (Exell) Versteegh & Sosef methanol stem bark extract, potent fractions and isolated Berberine alkaloid target both blood and liver stages of malaria parasites. J Ethnopharmacol, 2024
  79. Thinking About Berberine. Integr Med (Encinitas), 2023
  80. Effect of dietary supplementation with a new nutraceutical formulation on cardiometabolic risk factors: a double-blind, placebo-controlled, randomized clinical study. Arch Med Sci Atheroscler Dis, 2023
  81. Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial. Front Pharmacol, 2023
  82. An in vitro investigation of the effects of urolithins A and B on low-density lipoprotein uptake and its regulatory genes. Arch Med Sci, 2023
  83. Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome. Int J Appl Basic Med Res, 2023
  84. Spray-dried Solid Lipid Nanoparticles for Enhancing Berberine Bioavailability via Oral Administration. Curr Pharm Des, 2023
  85. Coptisine attenuates sepsis lung injury by suppressing LPS-induced lung epithelial cell inflammation and apoptosis. Allergol Immunopathol (Madr), 2023
  86. Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus® and placebo. Arch Med Sci, 2023
  87. Acyclic Triterpenoids from Alpinia katsumadai Seeds with Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Secretion Inhibitory Activity. ACS Omega, 2023
  88. Berberine-phospholipid nanoaggregate-embedded thiolated chitosan hydrogel for aphthous stomatitis treatment. Nanomedicine (Lond), 2023
  89. Dual-Step Controlled Release of Berberine Hydrochloride from the Trans-Scale Hybrids of Nanofibers and Microparticles. Biomolecules, 2023
  90. NaWRKY3 is a master transcriptional regulator of the defense network against brown spot disease in wild tobacco. J Exp Bot, 2023
  91. Berberine regulates glucose metabolism in largemouth bass by modulating intestinal microbiota. Front Physiol, 2023
  92. The Effect of Berberine Follow by Blue Light Irradiation and Valproic Acid on the Growth Inhibition of MDA-MB-231 Breast Cancer Cells. Appl Biochem Biotechnol, 2023
  93. Effects of n-butanol extract of Pulsatilla decoction on the NLRP3 inflammasome in macrophages infected with Candida albicans. J Ethnopharmacol, 2023
  94. Quality evaluation of berberine food supplements with high-field and compact 1H NMR spectrometers. J Pharm Biomed Anal, 2023
  95. [Nutraceuticals (monacolin K, berberine and coenzyme Q10) in patients with moderate hypercholesterolemia and low-moderate cardiovascular risk. Potential benefits of combined therapies]. Semergen, 2023
  96. Design, synthesis, and biological activity of 9-O-cinnamoylberberines as novel lipid-lowering agents. Nat Prod Res, 2023
  97. Simiao Wan and its ingredients alleviate type 2 diabetes mellitus via IRS1/AKT2/FOXO1/GLUT2 signaling. Front Nutr, 2022
  98. An open-label study on the short-term effects of a novel EFSA-compliant nutraceutical combination in mild-to-moderate hypercholesterolemia. Avicenna J Phytomed, 2022
  99. Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance. Front Cardiovasc Med, 2022
  100. A Gedunin-Type Limonoid, 7-Deacetoxy-7-Oxogedunin, from Andiroba (Carapa guianensis Aublet) Reduced Intracellular Triglyceride Content and Enhanced Autophagy in HepG2 Cells. Int J Mol Sci, 2022
  101. Functional Complementation of Anti-Adipogenic Phytonutrients for Obesity Prevention and Management. Nutrients, 2022
  102. Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis. Int J Mol Sci, 2022
  103. Jatrorrhizine Improves Endothelial Function in Diabetes and Obesity through Suppression of Endoplasmic Reticulum Stress. Int J Mol Sci, 2022
  104. Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation. Sci Rep, 2022
  105. A Composition of Phytonutrients for Glycemic and Weight Management. Nutrients, 2022
  106. The Effect of Berberine on Lipid Profile, Liver Enzymes, and Fasting Blood Glucose in Patients with Non-alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial. Med J Islam Repub Iran, 2022
  107. Integrated lipidomics and network pharmacology analysis to reveal the mechanisms of berberine in the treatment of hyperlipidemia. J Transl Med, 2022
  108. Recapsoma®: A Novel Mixture Based on Bergamot, Ipomoea Batatas, Policosanol Extracts and Liposomal Berberine for the Treatment of Hypercholesterolemia. Life (Basel), 2022
  109. The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial. Diabetol Metab Syndr, 2022
  110. Quality by design-based optimization of formulation and process parameters for berberine nanosuspension for enhancing its dissolution rate, bioavailability, and cardioprotective activity. J Food Biochem, 2022
  111. A microfluidic approach to fabricate sucrose decorated liposomes with increased uptake in breast cancer cells. Eur J Pharm Biopharm, 2022
  112. Cellular and Molecular Mechanisms and Effects of Berberine on Obesity-Induced Inflammation. Biomedicines, 2022
  113. Improvement of anticancer effect of berberine by salt formation modifications. Phytomedicine, 2022
  114. A green ultrasonic-assisted micellar extraction coupled with ultra-high performance liquid chromatography with photodiode array method for quantitative analysis of active ingredients in Yangxinshi Tablet. J Pharm Biomed Anal, 2022
  115. [Research of preparation quality markers of Yulian Tang with anti-inflammatory activity]. Zhongguo Zhong Yao Za Zhi, 2022
  116. Berberine suppresses the migration and invasion of colon cancer cells by inhibition of lipogenesis through modulation of promyelocytic leukemia zinc finger-mediated sterol-regulatory element binding proteins cleavage-activating protein ubiquitination. J Pharm Pharmacol, 2022
  117. The effect of anti-alcoholic gastric ulcer before and after vinegar-processed Yuanhu Zhitong prescription based on spectral-effect relationship. Biomed Chromatogr, 2022
  118. Effectiveness of Volatile Natural Deep Eutectic Solvents (VNADESs) for the Green Extraction of Chelidonium majus Isoquinoline Alkaloids. Molecules, 2022
  119. Berberine Suppresses Leukocyte Adherence by Downregulating CX3CL1 Expression and Shedding and ADAM10 in Lipopolysaccharide-Stimulated Vascular Endothelial Cells. Int J Mol Sci, 2022
  120. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients. J Adv Res, 2022
  121. Enhancing Anticancer Potency of a 13-Substituted Berberine Derivative with Cationic Liposomes. Chem Pharm Bull (Tokyo), 2022
  122. Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study. Cureus, 2022
  123. Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents. Bioorg Chem, 2022
  124. The Impact of Dietary Berberine Supplementation during the Transition Period on Blood Parameters, Antioxidant Indicators and Fatty Acids Profile in Colostrum and Milk of Dairy Goats. Vet Sci, 2022
  125. Separation and determination of the group-type composition of modern base and lubricating oils with a wide range of polarity, especially emitted to the environment. J Chromatogr B Analyt Technol Biomed Life Sci, 2022
  126. Molecular Basis of the Reinforced Effect of Berberine against Cutinase from Colletotrichum capsisi by Supplying Sodium Stearate as Dispersant. ACS Appl Bio Mater, 2022
  127. Cholesterol Microdomain Enhances the Biofilm Eradication of Antibiotic Liposomes. Adv Healthc Mater, 2022
  128. UPLC-MS/MS Profiling, Antioxidant, α-Glucosidase Inhibitory, Cholinesterase Inhibitory, and Cardiovascular Protection Potentials of Jialing 20 (Morus multicaulis Perr.) Mulberry Branch Extract. Foods, 2021
  129. Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. J Integr Med, 2021
  130. Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies. Front Pharmacol, 2021
  131. Acute and Long Term Effects of a Nutraceutical Combination on Lipid Profile, Glucose Metabolism and Vascular Function in Patients with Dyslipidaemia with and Without Cigarette Smoking. High Blood Press Cardiovasc Prev, 2021
  132. Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR. Exp Ther Med, 2021
  133. Berberine activates the β-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells. Eur J Pharmacol, 2021
  134. [Main components in butyl alcohol extract of Baitouweng Decoction inhibited neutrophil chemotaxis]. Zhongguo Zhong Yao Za Zhi, 2021
  135. Berberine, A Phytoalkaloid, Inhibits Inflammatory Response Induced by LPS through NF-Kappaβ Pathway: Possible Involvement of the IKKα. Molecules, 2021
  136. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health, 2021
  137. Structure-activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents. Bioorg Chem, 2021
  138. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol, 2021
  139. Nanoformulation and Evaluation of Oral Berberine-Loaded Liposomes. Molecules, 2021
  140. Analysis of Monacolins and Berberine in Food Supplements for Lipid Control: An Overview of Products Sold on the Italian Market. Molecules, 2021
  141. Beneficial Metabolic Effect of a Nutraceuticals Combination (Monacolin K, Yeasted Red Rice, Polyphenolic Extract of Annurca Apple and Berberine) on Acquired Hypercholesterolemia: A Prospective Analysis. Metabolites, 2021
  142. Protective effect of berberine against LPS-induced endothelial cell injury via the JNK signaling pathway and autophagic mechanisms. Bioengineered, 2021
  143. Synthesis of Moracin C and Its Derivatives with a 2-arylbenzofuran Motif and Evaluation of Their PCSK9 Inhibitory Effects in HepG2 Cells. Molecules, 2021
  144. Oxyberberine Prevented Lipopolysaccharide-Induced Acute Lung Injury through Inhibition of Mitophagy. Oxid Med Cell Longev, 2021
  145. Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α. Drug Deliv, 2021
  146. Altered gene expression and root thebaine production in polyploidized and methyl jasmonate-elicited Papaver bracteatum Lindl. Plant Physiol Biochem, 2021
  147. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies. Eur J Pharmacol, 2021
  148. Discovery of C-9 Modified Berberine Derivatives as Novel Lipid-Lowering Agents. Chem Pharm Bull (Tokyo), 2021
  149. Oil-in-water nanoemulsions comprising Berberine in olive oil: biological activities, binding mechanisms to human serum albumin or holo-transferrin and QMMD simulations. J Biomol Struct Dyn, 2021
  150. Discovery of 7,9-Disulfatetrahydroberberine as Novel Lipid-Lowering Agents. ACS Omega, 2020
  151. Berberine reduces gut-vascular barrier permeability via modulation of ApoM/S1P pathway in a model of polymicrobial sepsis. Life Sci, 2020
  152. Comparative effect of nutraceuticals on lipid profile: a protocol for systematic review and network meta-analysis. BMJ Open, 2020
  153. The role of serum inflammatory cytokines and berberine in the insulin signaling pathway among women with polycystic ovary syndrome. PLoS One, 2020
  154. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free Radic Biol Med, 2020
  155. Berberine inhibits cancer cells growth by suppressing fatty acid synthesis and biogenesis of extracellular vesicles. Life Sci, 2020
  156. Berberine-Loaded Nanostructured Lipid Carriers Enhance the Treatment of Ulcerative Colitis. Int J Nanomedicine, 2020
  157. Furanasperterpenes A and B, two meroterpenoids with a novel 6/6/6/6/5 ring system from the marine-derived fungus Aspergillus terreus GZU-31-1. Bioorg Chem, 2020
  158. In Vitro Effect of Methanolic Extract of Argemone mexicana against Trichomonas vaginalis. Korean J Parasitol, 2020
  159. Berberine and its structural analogs have differing effects on functional profiles of individual gut microbiomes. Gut Microbes, 2020
  160. An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. Diabetes Metab Syndr Obes, 2020
  161. Modulatory Effect of Chelidonium majus Extract and Its Alkaloids on LPS-Stimulated Cytokine Secretion in Human Neutrophils. Molecules, 2020
  162. Berberine Attenuates Cholesterol Accumulation in Macrophage Foam Cells by Suppressing AP-1 Activity and Activation of the Nrf2/HO-1 Pathway. J Cardiovasc Pharmacol, 2020
  163. Berberine reduces inflammation of human dental pulp fibroblast via miR-21/KBTBD7 axis. Arch Oral Biol, 2020
  164. Could PCSK9 be a new therapeutic target of Eugenol? In vitro and in silico evaluation of hypothesis. Med Hypotheses, 2020
  165. Berberine Induces CYP2J2 Expression in Human U251 Glioma Cells via Regulation of Peroxisome Proliferator-Activated Receptor Alpha. Pharmacology, 2020
  166. In-vitro Synergistic Effect of Metformin and Berberine on High Glucose-induced Lipogenesis. Iran J Pharm Res, 2019
  167. Microarray Expression Profiling and Raman Spectroscopy Reveal Anti-Fatty Liver Action of Berberine in a Diet-Induced Larval Zebrafish Model. Front Pharmacol, 2019
  168. Berberine as Source of Antiproliferative Hybrid Compounds: In Vitro Antiproliferative Activity and Quantitative Structure-activity Relationship. Anticancer Agents Med Chem, 2019
  169. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia. Acta Pharm Sin B, 2019
  170. Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments. PLoS One, 2019
  171. Inhibitory effects of berberine on proinflammatory M1 macrophage polarization through interfering with the interaction between TLR4 and MyD88. BMC Complement Altern Med, 2019
  172. Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. Nutr Metab Cardiovasc Dis, 2019
  173. Ameliorative Effect of Berberine on Neonatally Induced Type 2 Diabetic Neuropathy via Modulation of BDNF, IGF-1, PPAR-γ, and AMPK Expressions. Dose Response, 2019
  174. Hypolipidemic effects of herbal extracts by reduction of adipocyte differentiation, intracellular neutral lipid content, lipolysis, fatty acid exchange and lipid droplet motility. Sci Rep, 2019
  175. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med, 2019
  176. Anionic and Cationic Vitamin E-TPGS Mixed Polymeric Phospholipid Micellar Vehicles. Methods Mol Biol, 2019
  177. Berberine Influences Blood Glucose via Modulating the Gut Microbiome in Grass Carp. Front Microbiol, 2019
  178. Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER. Sci Rep, 2019
  179. Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases. Nat Commun, 2019
  180. Berberine Facilitates Angiogenesis Against Ischemic Stroke Through Modulating Microglial Polarization via AMPK Signaling. Cell Mol Neurobiol, 2019
  181. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med, 2019
  182. Liquid crystalline nanoreservoir releasing a highly skin-penetrating berberine oleate complex for psoriasis management. Nanomedicine (Lond), 2019
  183. Dietary Polyphenols Protect Against Oleic Acid-Induced Steatosis in an in Vitro Model of NAFLD by Modulating Lipid Metabolism and Improving Mitochondrial Function. Nutrients, 2019
  184. In Vitro Susceptibility of Berberine Combined with Antifungal Agents Against the Yeast Form of Talaromyces marneffei. Mycopathologia, 2019
  185. Berberine ameliorates lipopolysaccharide-induced acute lung injury via the PERK-mediated Nrf2/HO-1 signaling axis. Phytother Res, 2019
  186. Berberrubine and its analog, hydroxypropyl-berberrubine, regulate LDLR and PCSK9 expression via the ERK signal pathway to exert cholesterol-lowering effects in human hepatoma HepG2 cells. J Cell Biochem, 2019
  187. Berberine Ameliorates Periodontal Bone Loss by Regulating Gut Microbiota. J Dent Res, 2019
  188. Effects of a nutraceutical combination of fermented red rice, liposomal berberine, and curcumin on lipid and inflammatory parameters in patients with mild-to-moderate hypercholesterolemia: an 8-week, open-label, single-arm pilot study. Arch Med Sci Atheroscler Dis, 2018
  189. Combination of Berberine with Resveratrol Improves the Lipid-Lowering Efficacy. Int J Mol Sci, 2018
  190. Different age-independent effects of nutraceutical combinations on endothelium-mediated coronary flow reserve. Immun Ageing, 2018
  191. Berberine alleviates endothelial glycocalyx degradation and promotes glycocalyx restoration in LPS-induced ARDS. Int Immunopharmacol, 2018
  192. 9-O-benzoyl-substituted berberine exerts a triglyceride-lowering effect through AMPK signaling pathway in human hepatoma HepG2 cells. Environ Toxicol Pharmacol, 2018
  193. In Vitro Antidiabetic Activity and Mechanism of Action of Brachylaena elliptica (Thunb.) DC. Evid Based Complement Alternat Med, 2018
  194. The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins. Chem Biol Interact, 2018
  195. Berberine ameliorates blockade of autophagic flux in the liver by regulating cholesterol metabolism and inhibiting COX2-prostaglandin synthesis. Cell Death Dis, 2018
  196. Sodium dodecyl sulfate sensitized switchable solvent liquid-phase microextraction for the preconcentration of protoberberine alkaloids in Rhizoma coptidis. J Sep Sci, 2018
  197. Inhalable multi-compartmental phospholipid enveloped lipid core nanocomposites for localized mTOR inhibitor/herbal combined therapy of lung carcinoma. Eur J Pharm Biopharm, 2018
  198. Berberine protects the liver and kidney against functional disorders and histological damages induced by ferrous sulfate. Iran J Basic Med Sci, 2018
  199. Hyaluronate/lactoferrin layer-by-layer-coated lipid nanocarriers for targeted co-delivery of rapamycin and berberine to lung carcinoma. Colloids Surf B Biointerfaces, 2018
  200. Synergistic anticancer effects of nanocarrier loaded with berberine and miR-122. Biosci Rep, 2018
  201. Effectiveness and Safety of Dietetic Supplementation of a New Nutraceutical on Lipid Profile and Serum Inflammation Biomarkers in Hypercholesterolemic Patients. Molecules, 2018
  202. Biological-Profiling-Based Systematic Analysis of Rhizoma Coptidis from Different Growing Regions and Its Anticholesterol Biosynthesis Activity on HepG2 Cells. Mol Pharm, 2018
  203. Proteomics analysis reveals a potential new target protein for the lipid-lowering effect of Berberine8998. Acta Pharmacol Sin, 2018
  204. Berberine Protects Against Palmitate-Induced Apoptosis in Tubular Epithelial Cells by Promoting Fatty Acid Oxidation. Med Sci Monit, 2018
  205. Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway. Biochem Biophys Res Commun, 2018
  206. Contact Angle Measurements: an Alternative Approach Towards Understanding the Mechanism of Increased Drug Dissolution from Ethylcellulose Tablets Containing Surfactant and Exploring the Relationship Between Their Contact Angles and Dissolution Behaviors. AAPS PharmSciTech, 2018
  207. Berberine Encapsulated PLGA-PEG Nanoparticles Modulate PCSK-9 in HepG2 Cells. Cardiovasc Hematol Disord Drug Targets, 2018
  208. Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction. Int J Mol Med, 2018
  209. Bioactive-Chylomicrons for Oral Lymphatic Targeting of Berberine Chloride: Novel Flow-Blockage Assay in Tissue-Based and Caco-2 Cell Line Models. Pharm Res, 2018
  210. Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome. Minerva Cardioangiol, 2018
  211. Predictive QSAR modeling study on berberine derivatives with hypolipidemic activity. Chem Biol Drug Des, 2018
  212. Effect of berberine on lipopolysaccharide-induced monocyte chemotactic protein-1 and interleukin-8 expression in a human retinal pigment epithelial cell line. Int Ophthalmol, 2018
  213. Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. Ther Clin Risk Manag, 2017
  214. Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. Int J Nanomedicine, 2017
  215. Berberine Attenuates NLRP3 Inflammasome Activation in Macrophages to Reduce the Secretion of Interleukin-1β. Ann Clin Lab Sci, 2017
  216. Nanoemulsion-based delivery system for enhanced oral bioavailability and caco-2 cell monolayers permeability of berberine hydrochloride. Drug Deliv, 2017
  217. Impacts of berberine on oxidized LDL-induced proliferation of human umbilical vein endothelial cells. Am J Transl Res, 2017
  218. Dispersive admicelle solid-phase extraction based on sodium dodecyl sulfate coated Fe3 O4 nanoparticles for the selective adsorption of three alkaloids in Gegen-Qinlian oral liquid before high-performance liquid chromatography. J Sep Sci, 2017
  219. [Preliminary study on premixed materials of emulsion gel]. Zhongguo Zhong Yao Za Zhi, 2017
  220. Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. Sci Rep, 2017
  221. Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. Theranostics, 2017
  222. Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin. Nutr Metab Cardiovasc Dis, 2017
  223. PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency. Drug Deliv, 2017
  224. Comprehensive evaluation of SCFA production in the intestinal bacteria regulated by berberine using gas-chromatography combined with polymerase chain reaction. J Chromatogr B Analyt Technol Biomed Life Sci, 2017
  225. Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. Mol Nutr Food Res, 2017
  226. Berberine as a chemical and pharmacokinetic marker of the butanol-extracted Food Allergy Herbal Formula-2. Int Immunopharmacol, 2017
  227. Mitochondria play an important role in the cell proliferation suppressing activity of berberine. Sci Rep, 2017
  228. Berberine-sonodynamic therapy induces autophagy and lipid unloading in macrophage. Cell Death Dis, 2017
  229. Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia. Clin Pharmacol, 2017
  230. Evaluation of herb-drug interaction of a polyherbal Ayurvedic formulation through high throughput cytochrome P450 enzyme inhibition assay. J Ethnopharmacol, 2017
  231. [Determination of six alkaloids in six types of Coptidis Rhizoma pieces by RP-HPLC and spectrum-effect relationships with anti-diabetes pharmacodynamics data]. Zhongguo Zhong Yao Za Zhi, 2016
  232. Pterosin Sesquiterpenoids from Pteris cretica as Hypolipidemic Agents via Activating Liver X Receptors. J Nat Prod, 2016
  233. Effect of Diabetea tea ™ consumption on inflammatory cytokines and metabolic biomarkers in type 2 diabetes patients. J Ethnopharmacol, 2016
  234. Visualization of Stepwise Drug-Micelle Aggregate Formation and Correlation with Spectroscopic and Calorimetric Results. J Phys Chem B, 2016
  235. ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. J Mol Endocrinol, 2016
  236. High fat diet aggravates the nephrotoxicity of berberrubine by influencing on its pharmacokinetic profile. Environ Toxicol Pharmacol, 2016
  237. Tetrahydroberberrubine attenuates lipopolysaccharide-induced acute lung injury by down-regulating MAPK, AKT, and NF-κB signaling pathways. Biomed Pharmacother, 2016
  238. The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Evid Based Complement Alternat Med, 2016
  239. Berberine Preconditioning Protects Neurons Against Ischemia via Sphingosine-1-Phosphate and Hypoxia-Inducible Factor-1[Formula: see text]. Am J Chin Med, 2016
  240. Beneficial Effects of Berberine on Oxidized LDL-Induced Cytotoxicity to Human Retinal Müller Cells. Invest Ophthalmol Vis Sci, 2016
  241. Berberine as a photosensitizing agent for antitumoral photodynamic therapy: Insights into its association to low density lipoproteins. Int J Pharm, 2016
  242. Development and evaluation of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate-mixed polymeric phospholipid micelles of berberine as an anticancer nanopharmaceutical. Int J Nanomedicine, 2016
  243. Berberine Decreased Inducible Nitric Oxide Synthase mRNA Stability through Negative Regulation of Human Antigen R in Lipopolysaccharide-Induced Macrophages. J Pharmacol Exp Ther, 2016
  244. Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Curr Med Res Opin, 2016
  245. Myocardial Salvaging Effects of Berberine in Experimental Diabetes Co-Existing with Myocardial Infarction. J Clin Diagn Res, 2016
  246. Berberine is a potent agonist of peroxisome proliferator activated receptor alpha. Front Biosci (Landmark Ed), 2016
  247. Yeast extract induction of sanguinarine biosynthesis is partially dependent on the octadecanoic acid pathway in cell cultures of Argemone mexicana L., the Mexican poppy. Biotechnol Lett, 2016
  248. Monodisperse microparticles loaded with the self-assembled berberine-phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency. Eur J Pharm Biopharm, 2016
  249. Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. PLoS One, 2016
  250. Synergetic cholesterol-lowering effects of main alkaloids from Rhizoma Coptidis in HepG2 cells and hypercholesterolemia hamsters. Life Sci, 2016
  251. Drug approvals in India - Authors' reply. Lancet Diabetes Endocrinol, 2016
  252. Drug approvals in India. Lancet Diabetes Endocrinol, 2016
  253. Drug approvals in India. Lancet Diabetes Endocrinol, 2016
  254. [Efficient and rapid liquid reduction animal model]. Zhongguo Zhong Yao Za Zhi, 2015
  255. [Correlation of HPLC Characteristic Spectra of Vinegar Corydalis Rhizoma Decoction Pieces, Water Decoction and Formula Granules]. Zhong Yao Cai, 2015
  256. Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols, and Berberine) in Patients with Low-Moderate Risk Hypercholesterolemia: A Double-Blind, Placebo-Controlled Study. Curr Ther Res Clin Exp, 2015
  257. A Single Arm Pilot Study of Effects of Berberine on the Menstrual Pattern, Ovulation Rate, Hormonal and Metabolic Profiles in Anovulatory Chinese Women with Polycystic Ovary Syndrome. PLoS One, 2015
  258. Understanding the ultrastructural aspects of berberine-induced skin-darkening activity in the toad, Bufo melanostictus, melanophores. J Microsc Ultrastruct, 2015
  259. Indian endocrinologists start debate on diabetes drug. BMJ, 2015
  260. The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol, 2015
  261. Ketosis may promote brain macroautophagy by activating Sirt1 and hypoxia-inducible factor-1. Med Hypotheses, 2015
  262. [Regulatory effect of coptisine on key genes involved in cholesterol metabolism]. Zhongguo Zhong Yao Za Zhi, 2015
  263. Remodeling of Tight Junctions and Enhancement of Barrier Integrity of the CACO-2 Intestinal Epithelial Cell Layer by Micronutrients. PLoS One, 2015
  264. Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma. Mol Med Rep, 2015
  265. Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway. PLoS One, 2015
  266. Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice. Expert Rev Endocrinol Metab, 2015
  267. Improve bile duct-targeted drug delivery and therapeutic efficacy for cholangiocarcinoma by cucurbitacin B loaded phospholipid complex modified with berberine hydrochloride. Int J Pharm, 2015
  268. Three-phase solvent systems for the comprehensive separation of a wide variety of compounds from Dicranostigma leptopodum by high-speed counter-current chromatography. J Sep Sci, 2015
  269. CjbHLH1 homologs regulate sanguinarine biosynthesis in Eschscholzia californica cells. Plant Cell Physiol, 2015
  270. A room-temperature protocol to access isoquinolines through Ag(I) catalysed annulation of o-(1-alkynyl)arylaldehydes and ketones with NH4OAc: elaboration to berberine and palmatine. Org Biomol Chem, 2015
  271. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes, 2015
  272. Synergy among thymol, eugenol, berberine, cinnamaldehyde and streptomycin against planktonic and biofilm-associated food-borne pathogens. Lett Appl Microbiol, 2015
  273. In silico target fishing for the potential bioactive components contained in Huanglian Jiedu Tang (HLJDD) and elucidating molecular mechanisms for the treatment of sepsis. Chin J Nat Med, 2015
  274. In vitro anti-proliferative activity of Argemone gracilenta and identification of some active components. BMC Complement Altern Med, 2015
  275. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem, 2015
  276. A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. Mol Biosyst, 2015
  277. The natural compound berberine positively affects macrophage functions involved in atherogenesis. Nutr Metab Cardiovasc Dis, 2015
  278. Delivery of berberine using chitosan/fucoidan-taurine conjugate nanoparticles for treatment of defective intestinal epithelial tight junction barrier. Mar Drugs, 2014
  279. Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation. Biol Pharm Bull, 2014
  280. Effects of berberine in the gastrointestinal tract - a review of actions and therapeutic implications. Am J Chin Med, 2014
  281. Potent in vitro synergism of fusidic acid (FA) and berberine chloride (BBR) against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). World J Microbiol Biotechnol, 2014
  282. Influence of vinegar and wine processing on the alkaloid content and composition of the traditional Chinese medicine Corydalis Rhizoma (Yanhusuo). Molecules, 2014
  283. The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1. Int J Mol Med, 2014
  284. RCN1/OsABCG5, an ATP-binding cassette (ABC) transporter, is required for hypodermal suberization of roots in rice (Oryza sativa). Plant J, 2014
  285. Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-κB/p65, Akt and MAPK pathway in THP-1 cells. Pharmacol Rep, 2014
  286. Enhancing the antitumor activity of berberine hydrochloride by solid lipid nanoparticle encapsulation. AAPS PharmSciTech, 2014
  287. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. Int J Pharm, 2014
  288. Multitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytes. Integr Cancer Ther, 2014
  289. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. Fitoterapia, 2014
  290. Ameliorative effect of Pracparatum mungo extract on high cholesterol diets in hamsters. Food Funct, 2014
  291. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. Arterioscler Thromb Vasc Biol, 2014
  292. In Vitro Screening for Antihepatic Steatosis Active Components within Coptidis Rhizoma Alkaloids Extract Using Liver Cell Extraction with HPLC Analysis and a Free Fatty Acid-Induced Hepatic Steatosis HepG2 Cell Assay. Evid Based Complement Alternat Med, 2013
  293. Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4. Mediators Inflamm, 2013
  294. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol, 2013
  295. [Preparation and in vitro evaluation of self-assembled beads drug delivery system of berberine hydrochloride]. Zhongguo Zhong Yao Za Zhi, 2013
  296. Selective extraction of berberine and palmatine from Huangbai powder. Pak J Pharm Sci, 2013
  297. The complete chloroplast genome sequence of Mahonia bealei (Berberidaceae) reveals a significant expansion of the inverted repeat and phylogenetic relationship with other angiosperms. Gene, 2013
  298. Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells. J Ethnopharmacol, 2013
  299. Endocannabinoid metabolism in the prefrontal cortex in schizophrenia. Schizophr Res, 2013
  300. Berberine suppresses Th17 and dendritic cell responses. Invest Ophthalmol Vis Sci, 2013
  301. Smart photothermal-triggered bilayer phase transition in AuNPs-liposomes to release drug. Langmuir, 2013
  302. Berberine‑attenuated monocyte adhesion to endothelial cells induced by oxidized low‑density lipoprotein via inhibition of adhesion molecule expression. Mol Med Rep, 2013
  303. Derivatives of the cationic plant alkaloids berberine and palmatine amplify protonophorous activity of fatty acids in model membranes and mitochondria. Mitochondrion, 2013
  304. Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY), 2012
  305. [Effect of berberine hydrochloride on the secretion of monocyte chemoattractant protein-1 from human periodontal ligament cells in vitro]. Zhonghua Kou Qiang Yi Xue Za Zhi, 2012
  306. Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer. Minerva Ginecol, 2012
  307. On-line sample concentration and determination of cationic alkaloids in human plasma by micelle to solvent stacking in capillary zone electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci, 2012
  308. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes, 2012
  309. Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol, 2012
  310. Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol, 2012
  311. Probing and trapping a sensitive conformation: amyloid-β fibrils, oligomers, and dimers. J Alzheimers Dis, 2012
  312. Structural studies on ligand-DNA systems: A robust approach in drug design. J Biosci, 2012
  313. Gracilariopsis persica from Persian Gulf Contains Bioactive Sterols. Iran J Pharm Res, 2012
  314. Formation and conformation of baicalin-berberine and wogonoside-berberine complexes. Chem Pharm Bull (Tokyo), 2012
  315. Improvement of benzylisoquinoline alkaloid productivity by overexpression of 3'-hydroxy-N-methylcoclaurine 4'-O-methyltransferase in transgenic Coptis japonica plants. Biol Pharm Bull, 2012
  316. The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients. Iran J Pharm Res, 2012
  317. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol, 2012
  318. Suppression of oxLDL-induced MMP-9 and EMMPRIN expression by berberine via inhibition of NF-κB activation in human THP-1 macrophages. Anat Rec (Hoboken), 2012
  319. The sequential exposure to jasmonate, salicylic acid and yeast extract promotes sanguinarine accumulation in Argemone mexicana cell cultures. Biotechnol Lett, 2012
  320. [Study on effect of berberine on modulating lipid and CPT I A gene expression]. Zhongguo Zhong Yao Za Zhi, 2011
  321. Decrease in the production of β-amyloid by berberine inhibition of the expression of β-secretase in HEK293 cells. BMC Neurosci, 2011
  322. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutrition Metab, 2011
  323. Novel mitochondria-targeted antioxidants: plastoquinone conjugated with cationic plant alkaloids berberine and palmatine. Pharm Res, 2011
  324. Effect of Natural Products on Commercial Oral Antidiabetic Drugs in Enhancing 2-Deoxyglucose Uptake by 3T3-L1 Adipocytes. Ther Adv Endocrinol Metab, 2011
  325. Berberine potentizes apoptosis induced by X-rays irradiation probably through modulation of gap junctions. Chin Med J (Engl), 2011
  326. Antitumor effects of the combination of cholesterol reducing drugs. Oncol Rep, 2011
  327. Vacuole-localized berberine bridge enzyme-like proteins are required for a late step of nicotine biosynthesis in tobacco. Plant Physiol, 2011
  328. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica, 2011
  329. A simplified and high-throughput chromogenic assay for testing tissue factor-dependent procoagulant activity. J Biomol Screen, 2011
  330. Thousand fold concentration of an alkaloid in capillary zone electrophoresis by micelle to solvent stacking. J Chromatogr A, 2011
  331. Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia. Am J Physiol Regul Integr Comp Physiol, 2011
  332. Fluorescence detection by intensity changes for high-performance thin-layer chromatography separation of lipids using automated multiple development. J Chromatogr A, 2011
  333. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation, 2011
  334. Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells. Eur J Pharmacol, 2011
  335. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E₂ and prostaglandin E₂ receptors. Carcinogenesis, 2011
  336. Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. Evid Based Complement Alternat Med, 2011
  337. Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med, 2010
  338. Activity and interactions of antibiotic and phytochemical combinations against Pseudomonas aeruginosa in vitro. Int J Biol Sci, 2010
  339. Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation. Eur J Pharmacol, 2010
  340. Anti-atherogenic effect of berberine on LXRalpha-ABCA1-dependent cholesterol efflux in macrophages. J Cell Biochem, 2010
  341. Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model. Anal Biochem, 2010
  342. Extractions of isoquinoline alkaloids with butanol and octanol. Fitoterapia, 2010
  343. Nutraceuticals for treatment of high blood pressure values in patients with metabolic syndrome. High Blood Press Cardiovasc Prev, 2009
  344. Berberine improves free-fatty-acid-induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator-activated receptor gamma and fatty acid transferase expressions. Metabolism, 2009
  345. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem, 2009
  346. [Studies on the chemical constituents of Phellodendron chinense]. Zhong Yao Cai, 2009
  347. Purification of alkaloids from Corydalis yanhusuo W. T. Wang using preparative 2-D HPLC. J Sep Sci, 2009
  348. Vacuolar transport of nicotine is mediated by a multidrug and toxic compound extrusion (MATE) transporter in Nicotiana tabacum. Proc Natl Acad Sci U S A, 2009
  349. Separation and detection of isoquinoline alkaloids using MEEKC coupled with field-amplified sample injection induced by ACN. Electrophoresis, 2009
  350. Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements. J Lipid Res, 2009
  351. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate, 2009
  352. Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy. J Med Chem, 2009
  353. Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. J Mol Cell Cardiol, 2009
  354. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine, 2008
  355. [Study on self-microemulsifying drug delivery system of Jiaotai Pill active components]. Zhong Yao Cai, 2008
  356. Biochemical pathways in the antiatherosclerotic effect of berberine. Chin Med J (Engl), 2008
  357. Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Bioorg Med Chem Lett, 2008
  358. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med, 2008
  359. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis, 2008
  360. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother, 2008
  361. [Effects of ginsenoside and berberine on secretion of immunosuppressive cytokines in lung carcinoma cell line PG]. Zhong Xi Yi Jie He Xue Bao, 2008
  362. Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity. J Hum Hypertens, 2008
  363. Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells. J Agric Food Chem, 2007
  364. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res, 2007
  365. Enhanced benzophenanthridine alkaloid production and protein expression with combined elicitor in Eschscholtzia californica suspension cultures. Biotechnol Lett, 2007
  366. Molecular cloning and characterization of methylenedioxy bridge-forming enzymes involved in stylopine biosynthesis in Eschscholzia californica. FEBS J, 2007
  367. Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. Biochem Biophys Res Commun, 2007
  368. Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway. Oncol Rep, 2006
  369. The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms. J Lipid Res, 2006
  370. Nonaqueous capillary electrophoresis coupled with laser-induced native fluorescence detection for the analysis of berberine, palmatine, and jatrorrhizine in Chinese herbal medicines. J Sep Sci, 2006
  371. The Galpha protein controls a pH-dependent signal path to the induction of phytoalexin biosynthesis in Eschscholzia californica. Plant Cell, 2006
  372. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res, 2006
  373. Anti-arthritic effects of Ephedra sinica STAPF herb-acupuncture: inhibition of lipopolysaccharide-induced inflammation and adjuvant-induced polyarthritis. J Pharmacol Sci, 2006
  374. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol, 2005
  375. Berberine--a novel approach to cholesterol lowering. Expert Opin Investig Drugs, 2005
  376. Cheap Chinese herb lowers cholesterol. Health News, 2005
  377. Modulation of apoptosis by berberine through inhibition of cyclooxygenase-2 and Mcl-1 expression in oral cancer cells. In Vivo, 2005
  378. Antiradical and antioxidant activities of alkaloids isolated from Mahonia aquifolium. Structural aspects. Bioorg Med Chem, 2004
  379. Molecular cloning and biochemical characterization of Candida albicans acyl-CoA:sterol acyltransferase, a potential target of antifungal agents. Biochem Biophys Res Commun, 2004
  380. Transport and uptake characteristics of a new derivative of berberine (CPU-86017) by human intestinal epithelial cell line: Caco-2. Acta Pharmacol Sin, 2003
  381. [The inhibit effect of berberine on human colon cell line cyclooxygenase-2]. Zhonghua Nei Ke Za Zhi, 2003
  382. Isoflavones as potentiators of antibacterial activity. J Agric Food Chem, 2003
  383. Transfer of cationic antibacterial agents berberine, palmatine, and benzalkonium through bimolecular planar phospholipid film and Staphylococcus aureus membrane. IUBMB Life, 2001
  384. HWY-289, a novel semi-synthetic protoberberine derivative with multiple target sites in Candida albicans. J Antimicrob Chemother, 2001
  385. Increased expression of Galpha(q/11) and of phospholipase-Cbeta1/4 in differentiated human NT2-N neurons: enhancement of phosphoinositide hydrolysis. J Neurochem, 2000
  386. Inhibition of Candida rugosa lipase by berberine and structurally related alkaloids, evaluated by high-performance liquid chromatography. Biosci Biotechnol Biochem, 1999
  387. Differential inhibitory effects of protoberberines on sterol and chitin biosyntheses in Candida albicans. J Antimicrob Chemother, 1999
  388. Analysis of traditional Chinese anticancer drugs by capillary electrophoresis. J Chromatogr A, 1998
  389. The Pseudomonas phytotoxin coronatine mimics octadecanoid signalling molecules of higher plants. FEBS Lett, 1994
  390. Inhibitory effects of phenolics on xanthine oxidase. Anticancer Res, 1994
  391. Histochemical probing of potato periderm with neutral red: a sensitive cytofluorochrome for the hydrophobic domain of suberin. Biotech Histochem, 1992
  392. Interaction of berberine with human platelet alpha 2 adrenoceptors. Life Sci, 1991
  393. [Evaluation of the antiatherosclerotic properties of natural compounds of plant origin on cell cultures of the human aortic intima]. Farmakol Toksikol, 1989
  394. Human cutaneous mast cells--a study of fixative and staining reactions in normal skin. Br J Dermatol, 1989
  395. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrob Agents Chemother, 1988
  396. Fluorescence study of liver-alcohol-dehydrogenase complexes with berberine and other ligands. Eur J Biochem, 1973
  397. Effect of berberine on the fatty acid composition of Vibrio cholerae and Vibrio cholerae biotype eltor. Indian J Med Res, 1970
Reviews 137
  1. Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease: A Narrative Review. Pharmaceuticals (Basel), 2026
  2. Brain-Gut Axis Perspective on Irritable Bowel Syndrome: The Role of Gut Microbiota and Therapeutic Strategies of Traditional Chinese Medicine. Am J Chin Med, 2026
  3. Comparative Efficacy of Herbal Products on Metabolic Parameters in Metabolic-Dysfunction Associated Liver Disease: A Systematic Review and Network Meta-Analysis. Gastro Hep Adv, 2026
  4. [Research progress on mechanisms and therapeutic potential of active components of TCM in intervening lipid metabolism reprogramming in colorectal cancer]. Zhongguo Zhong Yao Za Zhi, 2026
  5. [Research advance on regulation of SREBP pathway by TCM in prevention and treatment of hyperlipidemia]. Zhongguo Zhong Yao Za Zhi, 2026
  6. Microbiota-mediated mechanisms of natural products in atherosclerosis: focus on metabolic and inflammatory pathways. Front Endocrinol (Lausanne), 2026
  7. Nutraceutical enhancement of paraoxonase 1 activity in chronic inflammation: A systematic review of animal-based and plant-based nutraceuticals. Nutr Health, 2026
  8. Rewiring lipid metabolism in diabetic kidney disease: Pathogenic networks and the therapeutic convergence of natural products. Pathol Res Pract, 2026
  9. Review: natural compounds as PCSK9 inhibitors for antiviral therapy. Arch Microbiol, 2026
  10. Gut microbiome-blood cholesterol crosstalk: towards personalized strategies for dyslipidemia. Folia Microbiol (Praha), 2026
  11. Phytochemical Monomers Derived from Traditional Chinese Medicine May Prevent and Treat Atherosclerosis by Modulating the Macrophage Mitochondrial-Lysosomal Senescence Axis. Int J Gen Med, 2026
  12. Targeting lipophagy in atherosclerosis: Molecular mechanisms, pathogenesis and therapeutic interventions (Review). Mol Med Rep, 2026
  13. Molecular landscape of Berberine's therapeutic potential in gastrointestinal disorders. J Tradit Chin Med, 2026
  14. The complex relationship between cardiologists and lipid-lowering dietary supplements: Hate or love? Nutr Metab Cardiovasc Dis, 2026
  15. Role of Anti-Inflammatory and Antioxidant Properties of Natural Products in Curing Cardiovascular Diseases. Curr Issues Mol Biol, 2025
  16. Hepatocyte nuclear factor 1 in renal lipid metabolism: molecular mechanisms and therapeutic potentials. Cell Biol Toxicol, 2025
  17. Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks. Int J Mol Sci, 2025
  18. Berberine's impact on health: Comprehensive biological, pharmacological, and nutritional perspectives. Metabol Open, 2025
  19. Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets. Mol Biomed, 2025
  20. Functional Foods for Cholesterol Management: A Review of the Mechanisms, Efficacy, and a Novel Cholesterol-Lowering Capacity Index. Nutrients, 2025
  21. Botanical Antinutrients as Natural Modulators of Postprandial Hyperglycemia and Hyperlipidemia: A Narrative Review. Phytother Res, 2025
  22. Regulatory mechanisms of hepatocyte PCSK9 expression: translating mechanistic insights into potential nutraceuticals. Chin Med, 2025
  23. Endoplasmic Reticulum Stress and Liver Cancer: Regulation Through Natural Products. Chem Biodivers, 2025
  24. Nutraceutical Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Path to Liver Health. Nutrients, 2025
  25. The role of bioactive compounds in the management of metabolic and alcohol-related liver disease. Life Sci, 2025
  26. Berberis aristata DC. (Indian barberry): Current insight into botanical, phytochemical, and pharmacological aspects, pharmacokinetics, safety of use and modern therapeutic applications. Fitoterapia, 2025
  27. Nutrients and Natural Substances for Hypoglycemic Effects and Management in Diabetic Retinopathy. Nutrients, 2025
  28. Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent. Pharmaceuticals (Basel), 2025
  29. Phytochemicals in Obesity Management: Mechanisms and Clinical Perspectives. Curr Nutr Rep, 2025
  30. Adrenic acid: A promising biomarker and therapeutic target (Review). Int J Mol Med, 2025
  31. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol, 2024
  32. A Clinicians Guide to Recommending Common Cholesterol-Lowering Dietary Supplements. Am J Cardiovasc Drugs, 2024
  33. Protein Kinases in Obesity, and the Kinase-Targeted Therapy. Adv Exp Med Biol, 2024
  34. Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions. Pharmaceuticals (Basel), 2024
  35. Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials. Phytother Res, 2024
  36. The therapeutic potential of typical plant-derived compounds for the management of metabolic disorders. Phytother Res, 2024
  37. Dietary supplements: clinical cholesterol-lowering efficacy and potential mechanisms of action. Int J Food Sci Nutr, 2024
  38. A promising therapy for fatty liver disease: PCSK9 inhibitors. Phytomedicine, 2024
  39. Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment. Int J Mol Sci, 2024
  40. Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action. Biomed Pharmacother, 2024
  41. Berberine: A Multi-Target Natural PCSK9 Inhibitor with the Potential to Treat Diabetes, Alzheimer's, Cancer and Cardiovascular Disease. Curr Rev Clin Exp Pharmacol, 2024
  42. Bitter yet beneficial: The dual role of dietary alkaloids in managing diabetes and enhancing cognitive function. Biofactors, 2024
  43. Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review. Front Pharmacol, 2023
  44. Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development. Pharmacol Res, 2023
  45. Exploring the Impact of Nutrition on Non-Alcoholic Fatty Liver Disease Management: Unveiling the Roles of Various Foods, Food Components, and Compounds. Nutrients, 2023
  46. Supplements for Lipid Lowering: What Does the Evidence Show? Curr Cardiol Rep, 2023
  47. Ameliorating effects of berberine on sepsis-associated lung inflammation induced by lipopolysaccharide: molecular mechanisms and preclinical evidence. Pharmacol Rep, 2023
  48. Role of herbal medicine and gut microbiota in the prevention and treatment of obesity. J Ethnopharmacol, 2023
  49. Pharmacotherapeutic values of berberine: A Chinese herbal medicine for the human cancer management. J Biochem Mol Toxicol, 2023
  50. Nutraceutical activation of Sirt1: a review. Open Heart, 2022
  51. Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy. Nutrients, 2022
  52. Berberine: Ins and outs of a nature-made PCSK9 inhibitor. EXCLI J, 2022
  53. A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. Pharmacol Res, 2022
  54. Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review. Mol Biol Rep, 2022
  55. Protective effect of berberine against LPS-induced injury in the intestine: a review. Cell Cycle, 2022
  56. Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends. Molecules, 2022
  57. Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration. Nutrients, 2022
  58. Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. Molecules, 2022
  59. Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fatty liver disease. Biochem Pharmacol, 2022
  60. Berberine improves liver injury induced glucose and lipid metabolic disorders via alleviating ER stress of hepatocytes and modulating gut microbiota in mice. Bioorg Med Chem, 2022
  61. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J Adv Res, 2021
  62. Effects of Berberine on Atherosclerosis. Front Pharmacol, 2021
  63. Dietary agents in mitigating chemotherapy-related cognitive impairment (chemobrain or chemofog): first review addressing the benefits, gaps, challenges and ways forward. Food Funct, 2021
  64. Potential Role of Natural Products to Combat Radiotherapy and Their Future Perspectives. Molecules, 2021
  65. Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? Curr Atheroscler Rep, 2021
  66. A spotlight on underlying the mechanism of AMPK in diabetes complications. Inflamm Res, 2021
  67. Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. Front Immunol, 2021
  68. Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia. Pharmacol Res, 2021
  69. Competing tissue-specific functions for the Tribbles-1 plasma lipid associated locus. Curr Opin Lipidol, 2021
  70. Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot. Ann Agric Environ Med, 2021
  71. A review on pain-relieving activity of berberine. Phytother Res, 2021
  72. Multifunctional epiberberine mediates multi-therapeutic effects. Fitoterapia, 2020
  73. Immunomodulatory effects of berberine on the inflamed joint reveal new therapeutic targets for rheumatoid arthritis management. J Cell Mol Med, 2020
  74. Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs. Curr Top Med Chem, 2020
  75. Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies. Rev Physiol Biochem Pharmacol, 2020
  76. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives. Curr Eye Res, 2020
  77. Nano-based delivery systems for berberine: A modern anti-cancer herbal medicine. Colloids Surf B Biointerfaces, 2020
  78. Naturally Occurring PCSK9 Inhibitors. Nutrients, 2020
  79. The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials. Evid Based Complement Alternat Med, 2019
  80. Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer's disease. Cent Nerv Syst Agents Med Chem, 2019
  81. Investigating functional properties of barberry species: an overview. J Sci Food Agric, 2019
  82. Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. J Cardiovasc Pharmacol Ther, 2019
  83. Pharmacology of Nutraceuticals with Lipid Lowering Properties. High Blood Press Cardiovasc Prev, 2019
  84. The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease. High Blood Press Cardiovasc Prev, 2019
  85. Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Curr Pharm Des, 2019
  86. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol, 2019
  87. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. Am J Transl Res, 2018
  88. Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis. Cholesterol, 2018
  89. The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol, 2018
  90. Add-on therapy with traditional Chinese medicine: An efficacious approach for lipid metabolism disorders. Pharmacol Res, 2018
  91. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res, 2018
  92. Cholesterol-Lowering Nutraceuticals Affecting Vascular Function and Cardiovascular Disease Risk. Curr Cardiol Rep, 2018
  93. Lipid lowering agents of natural origin: An account of some promising chemotypes. Eur J Med Chem, 2017
  94. [Research progress of berberine in treatment of diabetic kidney disease]. Zhongguo Zhong Yao Za Zhi, 2017
  95. Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. Curr Opin Lipidol, 2017
  96. Nutraceutical approaches to metabolic syndrome. Ann Med, 2017
  97. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct, 2017
  98. Dietary Factors Promoting Brown and Beige Fat Development and Thermogenesis. Adv Nutr, 2017
  99. Mode of action of berberine on lipid metabolism: a new-old phytochemical with clinical applications? Curr Opin Lipidol, 2017
  100. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res, 2017
  101. Regulation of PCSK9 by nutraceuticals. Pharmacol Res, 2017
  102. Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. Curr Pharm Des, 2017
  103. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol, 2017
  104. Role of berberine in Alzheimer's disease. Neuropsychiatr Dis Treat, 2016
  105. Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition, 2016
  106. Novel nutraceutic therapies for the treatment of metabolic syndrome. World J Diabetes, 2016
  107. Functional food red yeast rice (RYR) for metabolic syndrome amelioration: a review on pros and cons. World J Microbiol Biotechnol, 2016
  108. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol, 2016
  109. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia, 2016
  110. Role of phytochemicals in the management of metabolic syndrome. Phytomedicine, 2016
  111. Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: The available clinical data. Phytomedicine, 2016
  112. A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. Avicenna J Phytomed, 2015
  113. Role of Nutraceuticals in Hypolipidemic Therapy. Front Cardiovasc Med, 2015
  114. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis, 2015
  115. Red Yeast Rice Plus Berberine: Practical Strategy for Promoting Vascular and Metabolic Health. Altern Ther Health Med, 2015
  116. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol, 2015
  117. Potential benefits of berberine in the management of perimenopausal syndrome. Oxid Med Cell Longev, 2015
  118. Therapeutic potential of berberine against neurodegenerative diseases. Sci China Life Sci, 2015
  119. Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol Pharmacol, 2015
  120. Learning from berberine: Treating chronic diseases through multiple targets. Sci China Life Sci, 2015
  121. Practical strategies for modulating foam cell formation and behavior. World J Clin Cases, 2014
  122. Nutraceuticals for the treatment of hypercholesterolemia. Eur J Intern Med, 2014
  123. Efficacy of polyphenolic ingredients of Chinese herbs in treating dyslipidemia of metabolic syndromes. J Integr Med, 2014
  124. Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. Curr Top Med Chem, 2014
  125. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol, 2014
  126. Novel penetrating cations for targeting mitochondria. Curr Pharm Des, 2013
  127. GPR40: a therapeutic target for mediating insulin secretion (review). Int J Mol Med, 2012
  128. Berberine: a potential multipotent natural product to combat Alzheimer's disease. Molecules, 2011
  129. [Advances of the mechanism study on berberine in the control of blood glucose and lipid as well as metabolism disorders]. Yao Xue Xue Bao, 2010
  130. Role of endothelin receptor A and NADPH oxidase in vascular abnormalities. Vasc Health Risk Manag, 2010
  131. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs, 2010
  132. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep, 2010
  133. Advance of studies on anti-atherosclerosis mechanism of berberine. Chin J Integr Med, 2010
  134. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. N Biotechnol, 2009
  135. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 2008
  136. Characterization of aqueous pores in plant cuticles and permeation of ionic solutes. J Exp Bot, 2006
  137. Recent findings on natural products with erectile-dysfunction activity. Phytochemistry, 2003
Other papers, not yet read by us 93
  1. Coptidis Rhizoma for Obesity, Diabetes, and Dyslipidemia: An Integrated Meta-Analysis and In Silico Study. Int J Mol Sci, 2026
  2. Comparative anti-obesity efficacy of high-interest natural products in preclinical models: a bibliometric and network meta-analysis. Food Funct, 2026
  3. Effects of a Multi-Component Nutraceutical (NUT2) on the Lipid Profile in Adults with Low-to-Moderate Cardiovascular Risk: A Randomized Placebo-Controlled Trial. Nutrients, 2026
  4. Berberine-associated lipid-inflammatory regulation in atherosclerosis: an integrative transcriptomic, single-cell, and in vivo study. Funct Integr Genomics, 2026
  5. Berberine restrains the expansion of colorectal cancer organoids by blocking cell cycle progression and reducing lipid synthesis. Front Immunol, 2026
  6. Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis. Front Psychiatry, 2026
  7. Hypolipidemic, anti-inflammatory, and neurotrophic effects of a multicomponent nutraceutical containing berberine, bergamot, and amaranth in mild-to-moderate hypercholesterolemia. Neuro Endocrinol Lett, 2025
  8. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol, 2025
  9. The effects of Gegen Qinlian decoction and its main constituents on glucolipid metabolic disorders in diabetes: an overview of systematic reviews and meta-analysis. Syst Rev, 2025
  10. Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia, and Glycemic Response Improvement in a 60-year-Old Male with Metabolic Syndrome Through a Personalized Six-Month Nutraceutical/Diet Protocol: A Case Report. Altern Ther Health Med, 2025
  11. Clinical Efficacy of Curcumin, Resveratrol, Silymarin, and Berberine on Cardio-Metabolic Risk Factors Among Patients With Type 2 Diabetes Mellitus: A Systemic Review and Bayesian Network Meta-Analysis. Phytother Res, 2025
  12. The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial. Eur J Nutr, 2025
  13. Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial. J Physiol Pharmacol, 2024
  14. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. J Transl Med, 2024
  15. Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection. Int J STD AIDS, 2023
  16. Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial. Eur Rev Med Pharmacol Sci, 2023
  17. RETRACTED: Short-Term Effect of Nutraceutical Fruit Juices on Lipid Metabolism in Patients with Acquired Hypercholesterolemia. Int J Mol Sci, 2023
  18. Berberine and health outcomes: An umbrella review. Phytother Res, 2023
  19. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. Front Nutr, 2022
  20. Protective effect of berberine in diabetic nephropathy: A systematic review and meta-analysis revealing the mechanism of action. Pharmacol Res, 2022
  21. Preventive Effect of Berberine on Postoperative Atrial Fibrillation. Circ Arrhythm Electrophysiol, 2022
  22. Berberine in Non-Alcoholic Fatty Liver Disease-A Review. Nutrients, 2022
  23. Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk. Semergen, 2022
  24. Effect of berberine and bicyclol on Chinese patients with nonalcoholic fatty liver disease: a retrospective study. Postgrad Med, 2022
  25. The effect of barberry (Berberis integerrima) on lipid profile and systemic inflammation in subjects with cardiovascular risk factors: a randomized controlled trial. BMC Complement Med Ther, 2022
  26. Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. Psychiatry Clin Neurosci, 2022
  27. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut Microbes, 2022
  28. Bile Acids, Gut Microbiome and the Road to Fatty Liver Disease. Compr Physiol, 2021
  29. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxid Med Cell Longev, 2021
  30. Berberine Phospholipid Is an Effective Insulin Sensitizer and Improves Metabolic and Hormonal Disorders in Women with Polycystic Ovary Syndrome: A One-Group Pretest-Post-Test Explanatory Study. Nutrients, 2021
  31. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res, 2021
  32. Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Nutrients, 2021
  33. Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial. Trials, 2021
  34. Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk. J Med Food, 2021
  35. Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. J Med Food, 2021
  36. The position of functional foods and supplements with a serum LDL-C lowering effect in the spectrum ranging from universal to care-related CVD risk management. Atherosclerosis, 2020
  37. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. Biomed Pharmacother, 2020
  38. Role of a berberine-based nutritional supplement in reducing diarrhea in subjects with functional gastrointestinal disorders. Minerva Gastroenterol Dietol, 2020
  39. Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients. J Med Food, 2020
  40. Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules-A Meta-Analysis. J Med Food, 2020
  41. A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Nutr, 2020
  42. The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension. High Blood Press Cardiovasc Prev, 2019
  43. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. Lipids Health Dis, 2019
  44. Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial. Biomed Res Int, 2019
  45. Polyalthia Clerodane Diterpene Potentiates Hypoglycemia via Inhibition of Dipeptidyl Peptidase 4. Int J Mol Sci, 2019
  46. Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phytother Res, 2019
  47. Polyherbal dietary supplementation for prediabetic adults: study protocol for a randomized controlled trial. Trials, 2019
  48. Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects. Drug Des Devel Ther, 2019
  49. Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease. Am J Cardiol, 2019
  50. NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial. Atherosclerosis, 2019
  51. Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. Am J Cardiol, 2019
  52. Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Press Cardiovasc Prev, 2018
  53. [Nutraceuticals: a useful tool for cardiologists to improve lipid profile?]. G Ital Cardiol (Rome), 2018
  54. Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in diabetic patients with dyslipidemia. Acta Biomed, 2018
  55. A Polyphenol-Based Multicomponent Nutraceutical in Dysmetabolism and Oxidative Stress: Results from a Pilot Study. J Diet Suppl, 2018
  56. A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors. Can J Physiol Pharmacol, 2017
  57. Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). Am J Cardiol, 2017
  58. Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study. Int J Mol Sci, 2017
  59. Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J Biol Regul Homeost Agents, 2017
  60. Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study. Drug Des Devel Ther, 2017
  61. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. Atheroscler Suppl, 2017
  62. Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis, 2017
  63. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med, 2016
  64. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res, 2016
  65. Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. Am J Cardiol, 2015
  66. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One, 2015
  67. Nutraceuticals for Serum Lipid and Blood Pressure Control in Hypertensive and Hypercholesterolemic Subjects at Low Cardiovascular Risk. Adv Ther, 2015
  68. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutr J, 2015
  69. Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev, 2015
  70. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol, 2015
  71. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One, 2014
  72. Berberine and monacolin effects on the cardiovascular risk profile of women with oestroprogestin-induced hypercholesterolemia. High Blood Press Cardiovasc Prev, 2014
  73. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol, 2014
  74. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 2013
  75. Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers. J Altern Complement Med, 2013
  76. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis, 2012
  77. Nutraceuticals for blood pressure control in patients with high-normal or grade 1 hypertension. High Blood Press Cardiovasc Prev, 2012
  78. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther, 2012
  79. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine, 2012
  80. Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome. Nutr Metab Cardiovasc Dis, 2012
  81. Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. Gynecol Endocrinol, 2012
  82. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol, 2012
  83. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol, 2012
  84. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol, 2012
  85. [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]. Zhongguo Zhong Yao Za Zhi, 2011
  86. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther, 2011
  87. Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome. Nutr Res, 2011
  88. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta, 2010
  89. Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial. J Bone Miner Metab, 2010
  90. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 2010
  91. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis, 2010
  92. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 2008
  93. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung, 2007

Other conditions Berberine has been studied for

Checked against PubMed on 2026-10-28. Everything we know about Berberine